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CHAPTER 1 
INTRODUCTION 
 
1.1. PROSTATE CANCER 
1.1.1. Epidemiology of prostate cancer 
Worldwide, prostate cancer (PCa) is the most common non-skin malignancy in men, with an estimate 
of 900 000 men diagnosed with PCa in 2008 (Ferlay et al. 2010). It is the sixth most common cause of 
cancer-related mortality in men worldwide, estimated to be responsible for 258 000 deaths in 2008 
(Ferlay et al. 2010). In Europe, PCa is the most frequently diagnosed cancer and the third leading 
cause of death amongst men (Ferlay et al. 2013).   
There are three well-established risk factors for PCa: increasing age, ethnic origin and genetic 
predisposition. Indeed, PCa is a disease of older men as the median age at diagnosis is 66 years  
(Howlader et al. 2013). Secondly, PCa is nearly 1.6 times more common in men of African descent 
than in white men, and black man are also twice as likely to die of PCa (Howlader et al. 2013). The 
reasons for this racial disparity are yet to be determined but may be a combination of inherited 
genetic, epigenetic and biochemical mechanisms. Lastly, heredity has been shown to be important 
since having a first-degree relative (brother or father) with PCa increases the risk for an individual by 
approximately two- to three-fold. If two or more first-line relatives are affected, the risk increases 5- 
to 11-fold (Bratt et al. 2002).  
 
1.1.2. Diagnosis and staging of prostate cancer 
1.1.2.1. Diagnosis of prostate cancer 
The main diagnostic tools include a digital rectal examination (DRE), serum concentration of 
prostate-specific antigen (PSA), and ultrasound-guided biopsies. PSA is a glycoprotein that is secreted 
by prostate epithelial cells, meaning that PSA values can be elevated both in benign and malignant 
conditions of the prostate. Additionally, PSA levels are not elevated in all cases of PCa. Although the 
PSA test was the major screening tool for PCa detection, it has drawbacks as 30-50% of patients are 
being overtreated, while many other patients are being undertreated (Cooperberg et al. 2005). 
Definitive diagnosis of PCa is based on histologic examination of the material obtained through 
biopsies.  
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1.1.2.2. Staging of prostate cancer 
The TNM staging system for prostate carcinoma is based on the size of the primary tumor, the extent 
of invaded lymph nodes and any metastases. The primary tumor can range from organ-confined to 
fully invasive (T1-T4), with or without lymph node involvement (N0 or N1), and in the absence or 
presence of distant metastases (M0 or M1). The Gleason grade is a histological parameter which is 
used for grading PCa. It measures the extent of glandular differentiation and classifies tumor patterns 
from 1 to 5 (most to least differentiated). According to current international conventions, the 
Gleason score detected in a prostate biopsy consists of the Gleason grade of the dominant (most 
extensive) carcinoma component plus the highest grade, regardless of its extent. In radical 
prostatectomy specimens, both the primary and secondary Gleason grade should be reported 
(Epstein et al. 2005, Heidenreich et al. 2014).  
 
1.1.2.3. Risk stratification of prostate cancer 
D’Amico and colleagues described three risk groups that predict the risk of recurrence following 
localized treatment of PCa. This is based on PSA values, the Gleason score and the clinical stage 
(overview in Table 1.1) (D'Amico et al. 1998).  
 
Table 1.1. Overview of the risk groups as defined by D’Amico and colleagues.  
Risk group PSA (ng/ml)  Gleason score  Clinical staging 
Low risk ≤ 10 And ≤ 6 And T1, T2a 
Intermediate risk > 10, ≤ 20 Or 7 Or T2b 
High risk > 20  Or ≥ 8 Or T2c or higher 
 
Nowadays, pre-treatment risk stratification models like the Partin table, d’Amico risk groups and 
Kattan nomograms, which combine serum PSA level, clinical staging and biopsy Gleason score, are 
used in order to better predict pathological stage at radical prostatectomy and the risk of disease 
recurrence following definitive local treatment (D'Amico et al. 1998, Eifler et al. 2013, Kattan et al. 
1998). Unfortunately, these stratification models have accuracies of only 75-85% and do not take 
into account the heterogeneity in genetic, molecular and physiological characteristics of the disease. 
Indeed, the reasons why some cancers progress slowly while others behave more aggressively are 
not well understood. At present, there are no markers to discriminate clinically relevant from 
indolent disease. Further improvement of the clinical management of PCa will only be possible by 
identifying biomarkers of PCa aggressiveness, which will not only enable a better selection of 
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patients who will benefit from radical treatment, but will also reduce the overtreatment of patients 
with indolent PCa.  
 
1.1.3. Treatment of prostate cancer 
1.1.3.1. Low-risk prostate cancer 
The treatments applied for localized PCa are dependent on the risk for progression that is associated 
with the tumor, while also taking into account the patient’s age and comorbidity. Men with low-risk 
PCa are good candidates for active surveillance. Here, patients are followed very closely and local 
therapy with curative intent is initiated if there are any signs of local tumor progression (as 
determined by Gleason score progression at rebiopsy). This reduces the overtreatment of patients, 
as only 30% of men will require delayed radical intervention (Klotz et al. 2010).  
Definitive but aggressive therapies for low-risk PCa are radical prostatectomy and radiation therapy. 
This active treatment is mainly recommended for patients with localized disease and a long life 
expectancy. Data show similar survival rates for patients with organ-confined disease who are 
treated with either of these methods (D'Amico et al. 1998). Radiation therapy can be administered 
externally (beam radiation therapy) or internally (brachytherapy). However, it is hard to justify such 
aggressive therapies with many side effects in patients with Gleason score 6, or in patients much 
older than 70 years (Heidenreich et al. 2014).  
 
1.1.3.2. Intermediate- and high-risk prostate cancer 
There is no currently accepted standard regarding the optimal treatment of men with high-risk, 
clinically localized PCa. Again, radical prostatectomy and radiation therapy are possibilities. Surgically 
removing the prostate gland in patients with intermediate-risk and high-risk PCa should always be 
accompanied by an extended pelvic lymphadenectomy to obtain optimal information about the 
extent of lymph node involvement (Joniau et al. 2013). This knowledge is important to counsel 
patients about the potential need for adjuvant treatment options (Heidenreich et al. 2014). When 
high-risk patients are primarily treated by surgery, 56% eventually require adjuvant or salvage 
radiation therapy or hormonal therapy (Hsu et al. 2007). When one chooses radiation therapy, this 
should always be accompanied by neoadjuvant androgen-deprivation therapy as this improves the 
overall survival rate (Heidenreich et al. 2014).  
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Figure 1.1. Overview of the most important treatments for PCa, according to the progression of the 
disease.  
 
Patients diagnosed with PCa who underwent local treatment with curative intent are usually 
followed for at least 10 years to monitor possible recurrence indicated by a rise in serum PSA levels 
(Heidenreich et al. 2014). An overview of the most important treatments for PCa can be found in 
Figure 1.1.  
 
1.1.3.3. Advanced, relapsed and castration-resistant prostate cancer 
Hormonal therapy is a collective name for different types of drugs. Luteinizing hormone-releasing 
hormone (LHRH) agonists are the standard of care in hormonal therapy. Chemical castration can also 
be accomplished by LHRH antagonists. They result in a rapid drop of serum androgens to castration 
levels, which is important for the treatment of symptomatic locally advanced or metastatic disease. 
Finally, antiandrogens like bicalutamide can be used, although not as monotherapy (Heidenreich et 
al. 2013). Patients treated with LHRH analogues are followed by measuring serum PSA and 
testosterone levels. When the castration level is no longer maintained one can switch to another 
LHRH analogue, LHRH antagonists or add an antiandrogen (Heidenreich et al. 2013).  
Patients treated with curative local therapies (radical prostatectomy or radiation therapy) can still 
relapse. When initially treated with radical prostatectomy, salvage radiation therapy is administered. 
When initially treated with radiation therapy, the therapeutic options are hormonal therapy or 
salvage radical prostatectomy (Heidenreich et al. 2013). Relapse after hormonal therapy is described 
as castration-resistant PCa (CRPC). Asymptomatic metastatic CRPC is still hormone-sensitive and can 
be treated with abiraterone acetate plus prednisone, while both symptomatic and asymptomatic 
CRPC can be treated with the chemotherapeutic drug docetaxel. The chemotherapy is mainly given 
to relief bone pain. Second-line treatments in CRPC can include enzalutamide or cabazitaxel plus 
prednisone. Because the latter therapeutic options are relatively new, there currently is no standard 
yet on the specific sequence of therapies (Heidenreich et al. 2013).  
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1.2. THE GENOMIC LANDSCAPE OF PROSTATE CANCER1 
From a molecular point of view, cancer can result from a combination of single nucleotide variants 
(SNVs), small insertions and deletions (indels), rearrangements, aberrant methylation and changes in 
copy number which thus lead to differences in expression of oncogenes or tumor suppressor genes. 
A single nucleotide change is defined as a polymorphism (SNP) when two or more alleles at one locus 
occur in the same population, each with appreciable frequency. When the frequency of occurrence is 
very low, it is called a single nucleotide variant (SNV).  
Recent advances in massively parallel sequencing technologies allow for the detection of all of the 
aforementioned changes, at a much greater sensitivity and coverage, and evenly important, also at a 
constantly decreasing cost. To increase the speed of analyses, one can choose for exome sequencing 
which allows the identification of SNVs and indels that affect the protein coding parts of the genome. 
Sequencing the whole genome, however, allows the additional detection of rearrangements and 
copy number changes. Alternatively, transcriptome sequencing not only provides data on gene 
expression, but can also be used to detect gene rearrangements at a lower cost than genome 
sequencing. In addition, these data can be linked with changes in DNA methylation obtained from 
high-throughput sequencing of immunoprecipitated methylated tumor DNA. Together, these 
techniques generate vast amounts of data that now need to be searched for correlations with 
disease outcome or responsiveness to specific treatments. Obtaining entire (epi)genomic and 
transcriptomic landscapes of PCa is contributing to the identification of targets for novel anticancer 
drug development. In the long run, they could assist in a better diagnosis and adequate selection of 
therapy tools in the settings of personalized medicine. 
 
1.2.1. Copy number and gene expression changes 
Large studies on biomolecules in biological samples coming from different sources are obstructed 
because the tissues have undergone different preservation protocols which will affect protein, RNA 
and lipids (Choudhury et al. 2012). DNA, however, is highly stable and this makes it a preferred 
choice to develop reliable biomarkers. Indeed, DNA extraction enables the detection of genome-wide 
copy number alterations (CNAs), genome-wide SNP analyses, whole exome sequencing or even 
whole genome sequencing of tumor samples (Lonigro et al. 2011). CNAs can result in the 
amplification of oncogenes or the deletion of tumor suppressors, and these changes could contribute 
significantly to cancer etiology. Global analyses of copy number profiles of primary tumors and 
                                               
1 This chapter is based on the review ‘The genomic landscape of prostate cancer’ by Lien Spans, Liesbeth 
Clinckemalie, Christine Helsen, Dirk Vanderschueren, Steven Boonen, Evelyne Lerut, Steven Joniau, Frank 
Claessens, as was published in Int J Mol Sci. 2013 May 24;14(6):10822-51. 
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metastases identified recurrent aberrations associated with PCa development and progression, 
including broad losses of 1p, 6q, 8p, 9p and losses of large regions of chromosomes 13, 15, 18 and 22 
(Reynolds 2008). Gains of 1q, 3q, 7q and 8q are also well described in PCa (Reynolds 2008). In 
addition, focal amplifications of the androgen receptor (AR) (Xq12) and homozygous focal deletions 
of PTEN (10q) and NKX3.1 (8p) are also frequent in PCa (Demichelis et al. 2009, Grasso et al. 2012, 
Lonigro et al. 2011, Taylor et al. 2010). A recent more comprehensive CNA study of 218 primary and 
metastatic tumors by Taylor et al. confirmed the earlier data, but added a significant role for somatic 
copy number increases of the NCOA2 gene, which encodes an AR coactivator (Taylor et al. 2010). 
Similarly, copy number variations of CHD1 occur in 8% of lethal CRPC samples (Grasso et al. 2012). 
CHD1 encodes an ATP-dependent chromatin-remodeling enzyme, previously reported as deregulated 
in PCa (Berger et al. 2011b). As was shown recently, some CNAs occur almost only in CRPC. Examples 
of these are amplification of PTK2 and YWHAZ which occur in less than 3% of primary PCas, but in 35-
48% of CRPC patients (Menon et al. 2013).  
PCa is a clinically heterogeneous disease meaning that the majority of cancer-affected prostates 
harbor multiple distinct primary tumor foci with different characteristics. High-resolution copy 
number changes from both primary tumor and different metastases revealed identical copy number 
changes, shared by all same-case cancer foci and defined by the same breakpoints in all multi-tumor 
cases (Boyd et al. 2012). This suggests that the genome copy number architecture was extremely 
homogeneous and conserved both within the primary tumor and between primary and metastatic 
tumors (Wu et al. 2012). This also indicates that metastatic PCas can have monoclonal origins and 
maintain the unique signature copy number pattern of the parent cancer clone (Boyd et al. 2012, Liu 
et al. 2009). This was confirmed recently by Haffner and colleagues, who demonstrated a clonal 
relationship between the primary tumor and metastases, both at the level of copy number changes 
and at the level of point mutations (Haffner et al. 2013). However, each focus will also accumulate a 
variable number of separate subclonally sustained genomic changes. So, although multiple tumor 
foci commonly arise from a single clone, this does not imply that the separate foci are biologically 
homogeneous. In conclusion, it is to be expected that multiple primary foci within one prostate 
indeed have the same genetic origin, although they may to some extent acquire distinct genetic 
lesions.  
Another study reported an increasing percentage of the genome affected by CNAs with increasing 
stage, grade and diagnostic PSA levels (Cheng et al. 2012). This is in agreement with the study from 
Taylor and colleagues who reported that metastases harbor more whole chromosome, chromosome 
arm and focal amplifications and deletions than primary tumors (Taylor et al. 2010). Their study 
revealed three regions of recurrent copy number loss associated with the TMPRSS2-ERG fusion: two 
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regions spanning the tumor suppressors PTEN and TP53, respectively and a third spanning the 
multigenic region at 3p14 (Taylor et al. 2010). These data revealed distinct subgroups with 
substantial differences in time to biochemical (PSA) relapse. More specifically two subgroups of 
primary tumors were defined, those with minimal CNAs and those with substantial alterations. The 
latter group included most of the metastatic samples with unfavorable prognosis (Taylor et al. 2010). 
Importantly, there is no correlation between high Gleason scores and these two subgroups, 
indicating that histology and copy number alterations are non-overlapping features (Taylor et al. 
2010). Hence, CNA could become useful as an additional clinical marker independent from Gleason 
scores.  
 
1.2.2. Gene fusions 
A second type of molecular alterations occurring in cancer is the fusion or rearrangement of genes. A 
large number of chromosomal rearrangements were primarily discovered in leukemias, lymphomas 
and sarcomas (Rowley 2001). The first report on gene rearrangements in solid tumors in general and 
PCa in particular, however, was reported in 2005, when Tomlins and colleagues applied a statistical 
approach termed cancer outlier profile analysis in combination with rapid amplification of cDNA 
ends, thus identifying the TMPRSS2-ERG, TMPRSS2-ETV1 and TMPRSS2-ETV4 fusions in PCa samples 
(Tomlins et al. 2006, Tomlins et al. 2005). 
 
1.2.2.1. Detection of ETS gene fusions in PCa 
The ERG, ETV1 and ETV4 genes belong to the family of v-ets erythroblastosis virus E26 oncogenes 
(ETS) which encode transcription factors characterized by a highly conserved, sequence-specific DNA-
binding domain, the so-called ETS domain (Donaldson et al. 1994). The TMPRSS2 gene encodes an 
androgen-regulated, type II transmembrane-bound serine protease that is highly expressed in 
normal prostate tissue as well as in neoplastic prostate epithelium (Vaarala et al. 2001a, Vaarala et 
al. 2001b). This explains why the gene fusion leads to the androgen-responsive, prostate-specific 
expression of these ETS transcription factors (Figure 1.2). The recurrent TMPRSS2-ETS fusion is by far 
the most common rearrangement described in any neoplasm, since it has been found in 
approximately 50% of all PCa cases examined (Perner et al. 2007).  
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Figure 1.2. Mechanism of androgen-regulated overexpression of ERG. TMPRSS2 and ERG are both 
located on chromosome 21 in the same transcriptional orientation and only 3 Mb apart from each 
other. In absence of the fusion, androgen stimulation will result binding of the AR to an enhancer 
upstream of TMPRSS2 and hence in transcription of TMPRSS2. The TMPRSS2-ERG fusion results in 
the androgen-regulated overexpression of ERG.  
 
Less common genomic rearrangements in PCa were identified later and involved SLC45A3, HERV-K, 
HNRPA2B1, KLK2 and C15orf21 as 5’ fusion partners of ETV1 and FKBP5 as fusion partner of ERG 
(Pflueger et al. 2011, Tomlins et al. 2007). SLC45A3 is a prostate-specific, androgen-responsive gene 
that has been found fused to ERG, ETV1, ETV5 and ELK4 (Esgueva et al. 2010, Han et al. 2008, 
Helgeson et al. 2008, Maher et al. 2009a, Rickman et al. 2009, Tomlins et al. 2007). Recently, a 
SNURF-ETV1 fusion formed in conjunction with a complex rearrangement event was detected. It 
involves the androgen-regulated 5’ fusion partner SNURF and it also led to marked overexpression of 
ETV1 (Weischenfeldt et al. 2013). An overview of all ETS gene fusions identified so far in PCa samples 
can be found in Table 1.2.  
Table 1.2. Overview of ETS gene fusions detected in samples of prostate cancer patients. The list is 
organized according to the 3’ fusion partner.  
5’ partner 3’ partner Reference 5’ partner 3’ partner Reference 
TMPRSS2 ERG (Tomlins et al. 2005) TMPRSS2 ETV1 (Tomlins et al. 2005) 
HERPUD1 ERG (Maher et al. 2009b) SLC45A3 ETV1 (Tomlins et al. 2007) 
SLC45A3 ERG (Han et al. 2008) C15orf21 ETV1 (Tomlins et al. 2007) 
NDRG1 ERG (Pflueger et al. 2009) HNRPA2B1 ETV1 (Tomlins et al. 2007) 
FKBP5 ERG (Pflueger et al. 2011) FLJ35294 ETV1 (Han et al. 2008) 
TMPRSS2 ETV4 (Tomlins et al. 2006) ACSL3 ETV1 (Attard et al. 2008) 
DDX5 ETV4 (Han et al. 2008) EST14 ETV1 (Hermans et al. 2008b) 
CANT1 ETV4 (Hermans et al. 2008a) HERVK17 ETV1 (Hermans et al. 2008b) 
KLK2 ETV4 (Hermans et al. 2008a) 
HERVK22q
11.23 
ETV1 (Tomlins et al. 2007) 
TMPRSS2 ETV5 (Helgeson et al. 2008) FOXP1 ETV1 (Hermans et al. 2008b) 
SLC45A3 ETV5 (Helgeson et al. 2008) KLK2 ETV1 (Pflueger et al. 2011) 
SLC45A3 FLI1 (Paulo et al. 2012) FUBP1 ETV1 (Lapuk et al. 2012) 
SLC45A3 ELK4 (Maher et al. 2009a) SNURF ETV1 (Weischenfeldt et al. 2013) 
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In general, the ETS transcription factors are considered poor therapeutic targets owing to their lack 
of enzymatic activity, their inaccessibility because of intranuclear activity and their dependence on 
interactions with other proteins to achieve specificity. Nevertheless, attempts are being made to 
develop compounds that interfere specifically with the function of ETS genes as transcription factors 
(Nhili et al. 2013). Alternatively, inhibitory molecules that target the TMPRSS2 promoter and/or 
control regions could also reduce ETS expression.  
 
1.2.2.2. Detection of non-ETS gene fusions in PCa 
Paired-end transcriptome sequencing identified genomic rearrangements involving genes of the RAF 
kinase pathway: SLC45A3-BRAF, AGTRAP-BRAF, ESRP1-RAF1, EPB41-BRAF and RAF1-ESRP1 (Beltran 
et al. 2012, Palanisamy et al. 2010). Some of the proteins encoded by these gene fusions, like BRAF, 
are well known drug targets, so the expression of these genes might become clinically useful in the 
future. Many other non-ETS gene fusions have been identified, although each of these fusions was 
detected only once (Lapuk et al. 2012, Maher et al. 2009a, Pflueger et al. 2011, Weischenfeldt et al. 
2013, Wu et al. 2012). Moreover, two novel 3’ fusion partners of TMPRSS2 have been identified: 
FKBP5 and CCDC21 (Pflueger et al. 2011, Weischenfeldt et al. 2013). Validation of the fusions 
involving FKBP5 led to the discovery of a complex triple fusion event with FKBP5 joined to TMPRSS2 
and ERG (Pflueger et al. 2011). In general, the non-ETS aberrations can occur both in TMPRSS2-ERG 
negative and positive cancers. 
 
1.2.2.3. The role of fusion genes in the molecular pathology of PCa 
Although there are more non-ETS gene fusions identified than ETS gene fusions, most of these have 
been detected only once. This is in contrast to the ETS gene fusions which occur at high frequencies 
in PCa patients, ranging from 15 to 70% depending on the clinical cohorts investigated. Of these ETS 
fusions, ERG rearrangements were identified in 53% of 540 patients (Esgueva et al. 2010). After ERG, 
ETV1 is the most commonly rearranged in about 5% of the patients (Attard et al. 2008). Other ETS 
genes, such as ETV4 and ETV5 may have rearrangement frequencies at or below 1-2%. 
The impact of the fusions on prognosis has been investigated in many clinical studies, but remains 
highly debated. A recent study involving 1039 radical prostatectomy tumors discovered that positive 
ERG rearrangement status is associated with younger age at diagnosis, lower serum PSA and lower 
prostate volume (Schaefer et al. 2013). In another cohort of 2800 PCas, no relation was found 
between ERG gene rearrangement and clinical outcome or tumor phenotype (Minner et al. 2011).  
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While the existing paradigm dictates that chromosomal rearrangements occur gradually over time, 
recent evidence suggests that in some cancers tens to hundreds of genomic rearrangements 
involving only one or a few chromosomes can occur in a cellular crisis resulting in cancer-causing 
lesions. This phenomenon, known as chromothripsis, was first described by Stephens and colleagues 
in a patient with chronic lymphocytic leukemia and several cancer cell lines (Stephens et al. 2011). In 
PCa, chromothripsis was reported one year later and was detected by the presence of triple fusion 
genes (Lapuk et al. 2012). Whole genome sequencing of seven high-risk primary tumors revealed 
complex inter- and intra-chromosomal events involving an exchange of ‘breakpoint arms’ generating 
a mix of chimeric chromosomes. There was, however, no loss of genetic material in contrast to what 
happens during chromothripsis (Berger et al. 2011b). These complex translocations will deregulate 
multiple genes in parallel and this may drive prostate tumorigenesis. To indicate the difference with 
chromothripsis, the latter form of rearrangements has been termed chromoplexy (Baca et al. 2013).  
The presence of the TMPRSS2-ERG fusion in 19% of high-grade prostatic intraepithelial neoplasia 
(PIN) lesions adjacent to cancer foci suggests that this fusion is an early event in the development of 
invasive PCa (Perner et al. 2007). In some TMPRSS2-ERG-positive tumors, rearrangement breakpoints 
occur preferentially within regions containing AR and ERG DNA binding sites, while in ETS fusion-
negative cells there is an inverse correlation with AR and ERG binding events, indicating alternative 
mechanisms for the genesis of breakpoints. This also suggests a causal link between the open 
chromatin structure linked to transcriptional activities at the genes involved and the mechanism of 
translocation (Berger et al. 2011b). A recent study reported on whole genome sequencing of 11 
patients with early onset PCa (Weischenfeldt et al. 2013). Despite an overall lower number of 
structural rearrangements in early onset PCa compared to elderly onset PCa, they detected an 
increase in balanced rearrangements and a higher fraction of gene rearrangements also affecting 
androgen-driven genes in early onset PCa (Weischenfeldt et al. 2013). This contrasts with the 
accumulation of non-androgen-associated structural rearrangements in elderly onset PCa, most of 
which correspond to copy number alterations with concomitant loss of genetic material. In terms of 
consequences for the oncogenic process, the authors conclude that most early onset PCas involve an 
androgen-driven pathogenic mechanism characterized by a marked abundance of balanced 
structural DNA rearrangements involving androgen-regulated genes (Weischenfeldt et al. 2013).  
The role of ERG overexpression in PCa development has been studied in transgenic mice expressing 
the ERG gene fusion product under androgen-regulation. These mice only develop PIN-like structures 
(Tomlins et al. 2008). The TMPRSS2-ERG fusion on its own is therefore insufficient to induce the 
development of invasive carcinoma, indicating that other (epi)genetic factors also contribute to the 
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initiation of PCa. However, the presence of the TMPRSS2-ERG gene fusion promotes PCa in both mice 
and humans when PTEN is concurrently lost (Carver et al. 2009, Casey et al. 2012, King et al. 2009).  
In conclusion, although a lot is known about the gene fusions in PCa, from a clinical point of view, 
further classification tools, probably independent as well as dependent of the fusion status, are 
needed to help determine the optimal patient-tailored treatment modalities. For some cases, like 
BRAF-fusion positive PCa, an optimal treatment with BRAF kinase inhibitors is already available in the 
clinic.  
 
1.2.3. Single base pair changes 
1.2.3.1. Single nucleotide variants (SNVs) 
1.2.3.1.1. The beginning of next-generation sequencing 
Targeted resequencing of 157 genes in 80 primary tumors and metastases confirmed that the AR was 
the most frequently mutated gene in PCa metastases (Taylor et al. 2010). While it is known that 
alteration of the AR through mutation, gene amplification or overexpression occurs exclusively in 
metastatic samples after hormone therapy, alterations of the AR pathway also occur in 56% of high 
volume primary tumors and were confirmed in 100% of the metastases (Goh et al. 2012). In addition, 
the nuclear receptor coactivator NCOA2 had a gain of expression or mutation in 8% of primary 
tumors and 37% of metastases. Integration of all the mutation data with copy number alterations 
and transcriptome data revealed that three well-known cancer pathways were commonly altered: 
PI3K, RAS/RAF and RB (Taylor et al. 2010).  
To study genomic changes in PCa, one can also study cell lines or tumors either grown in vitro or as 
xenografts in immunocompromised mice. This has the advantage that the response to cancer-
directed therapeutics can be monitored, but the disadvantages are that no corresponding normal 
tissue or DNA is available and that a number of the genomic changes will have arisen during the 
culturing and hence are not relevant for the study of tumorigenesis (Kumar et al. 2011). Despite this, 
TP53 was the most frequently mutated gene in the xenografts, and pathway analysis of genes 
mutated in castration-resistant compared to castration-sensitive pairs of tumor lines derived from 
the same PCa revealed a significant enrichment of the Wnt signaling pathway (Kumar et al. 2011).  
 
1.2.3.1.2. Large scale genomic analyses  
Berger and colleagues reported an average of 20 non-synonymous SNVs in seven high-risk primary 
PCas (Berger et al. 2011b). Only the SPTA1 gene, involved in erythroid cell shape specification, was 
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mutated in two out of seven tumors (Berger et al. 2011b). More recently, two studies explored the 
presence of SNVs in 112 primary tumors and 50 metastases respectively (Barbieri et al. 2012, Grasso 
et al. 2012). Both studies performed whole exome sequencing and reached an average of 120-fold 
coverage. Here, a median of 30 non-synonymous SNVs in the exome of primary PCas was detected. 
Most likely the higher exome sequence coverage in the latter two studies improved the detection of 
SNVs that are present at lower allelic fractions and thus explains the higher number of SNVs (Barbieri 
et al. 2012). Indeed, a recent genomic study with 30-40x coverage on 11 samples detected an 
average of only 16 non-synonymous SNVs (ranging from 3 to 55) (Weischenfeldt et al. 2013). Barbieri 
and colleagues reported twelve genes which were recurrently mutated and contained more 
mutations in PCa than expected by chance: PIK3CA, PTEN, TP53, SPOP, FOXA1, MED12, CDKN1B, 
ZNF595, THSD7B, NIPA2, C14orf49, and SCN11A (Figure 1.3) (Barbieri et al. 2012). Mutations in the 
PIK3CA, PTEN and TP53 genes were already well known to be involved in the tumorigenesis of PCa. 
CDKN1B was known to constrain prostate tumor growth in mice by inhibiting cell proliferation and 
cancer progression, but somatic substitutions had not been previously observed in this cell cycle 
regulator (Majumder et al. 2008). Several genes not previously known to undergo somatic alteration 
in PCa were enriched for mutations, including FOXA1, MED12, THSD7B, SCN11A, NIPA2, C14orf49 
and ZNF595 (Barbieri et al. 2012). Some of them affect the androgen signaling axis. The transcription 
factor FOXA1 regulates cell proliferation and promotes tumor progression in castration-resistant PCa 
(Imamura et al. 2012). Moreover, it can act as a pioneering factor for AR binding to chromatin and 
the protein level in primary tumors has been associated with disease outcome (Sahu et al. 2011). 
Mutations affecting MED12 were not previously observed in PCa, but had been reported in 70% of 
uterine leiomyomas (Makinen et al. 2011). MED12 is a subunit of the mediator complex that 
regulates transcription by bridging DNA regulatory sequences to the RNA polymerase II initiation 
complex (Taatjes 2010).  
The SPOP gene was mutated in 13% of the analyzed tumors (Barbieri et al. 2012). In additional 
cohorts, 6-15% of the tumors contained a SPOP mutation. In contrast to SPOP mutations detected in 
other cancer types, which are scattered over the entire length of the protein, the PCa mutations 
cluster in the substrate-binding cleft. Remarkably, the presence of a SPOP mutation was mutually 
exclusive with mutations in TP53, PTEN or the TMPRSS2-ERG rearrangement (Barbieri et al. 2012). 
SPOP encodes the substrate-binding subunit of an E3 ubiquitin ligase and hence is a modulator of 
stability for specific substrate proteins. Interestingly, it was shown recently that SPOP induces 
degradation of full length AR, while mutants of SPOP cannot promote AR destruction anymore (An et 
al. 2014).  
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Grasso et al. performed an exome sequencing study of metastatic biopsies of 50 lethal, heavily pre-
treated CRPCs and identified nine genes that were significantly mutated (Grasso et al. 2012). Of 
these, six were already reported as recurrently mutated in PCa: TP53, AR, ZFHX3, RB1, PTEN and APC 
(Grasso et al. 2012). Three other genes were novel for PCa: MLL2, CDK12 and OR5L1. MLL2 is a 
histone methyltransferase that mediates H3K4 trimethylation which is recurrently mutated in 
multiple cancers (Natarajan et al. 2010). The cyclin-dependent kinase CDK12 protects cells from 
genomic instability through regulation of expression of DNA damage response genes (Blazek et al. 
2011). As OR5L1 encodes an olfactory receptor, a role of this mutation in the oncogenic process is 
more difficult to envision. Grasso et al. also found that CHD1 is mutated or deleted in 8% of PCas. 
Using Oncomine, they detected focal deletions or mutations of CHD1 in 5.2% of 954 PCas, 96% of 
which were negative for the ETS-fusion. This integrated analysis identifies CHD1-/ETS- as a novel PCa 
subtype (Grasso et al. 2012). Together, their data suggest that aberrations in AR and interacting 
proteins, including chromatin/histone remodelers, ETS genes and known AR coregulators including 
FOXA1 are common in CRPC (Grasso et al. 2012).  
Integration of exome sequencing on primary PCa with RNA sequencing and copy number alteration 
revealed that the mutation rate in the mitochondrial genome was 55 times higher than that of the 
autosomes (Lindberg et al. 2012). More specifically, the electron transport chain was mutated in 
almost half of the tumors. Several of these mitochondrial SNVs were not yet reported, although 
closely related genes have been reported to be mutated in other cancers (Lindberg et al. 2012). For 
example, MLL3 was a novel gene detected to be mutated in PCa, while its close relative MLL2 has 
been previously reported in PCa. However, the biological and clinical relevance of these mutations 
needs to be documented further. 
In conclusion, with over 200 PCa sequences reported, we can conclude that point mutations in PCa 
are not as rare as initially expected. While very few genes are recurrently affected, the mutations 
recur in specific signaling pathways like the androgen signaling pathway. Moreover, until studies are 
undertaken in substantially larger cohorts, it will be difficult to attribute significance to the different 
SNVs. We therefore merged the lists of SNVs detected in the aforementioned studies, both for 
primary tumors and metastases. The most frequently mutated genes are represented in Figure 1.3.   
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Figure 1.3. Overview of the most frequently mutated genes in primary and metastatic prostate 
cancer. Gene lists were taken from Taylor et al. 2010; Berger et al. 2011; Robbins et al. 2011, Barbieri 
et al. 2012; Beltran et al. 2012; Grasso et al. 2012; Lindberg et al. 2012; Lindberg et al. 2013 and 
Weischenfeldt et al. 2013. The cumulative number of mutations is given on the right. The names of 
genes that are recurrently mutated both in primary tumors and in metastases are bold and 
underlined.  
 
1.2.3.1.3. Future perspectives: Prostate cancer is a multi-focal disease 
Because of the clinical heterogeneity of PCa and the presence of multiple distinct primary tumor foci, 
it needs to be established whether these foci are identical, similar or arose independently. Also, it 
has to be established whether the so-called index lesion is indeed of clinical relevance and harbors 
the site where metastases evolve from. In one study, four primary tumors, three of which harbored 
multiple foci, were sampled to verify the monoclonal or polyclonal origin of these different foci. No 
common SNVs were detected in the different foci of these primary tumors, indicating that the foci 
are independent cancers (Lindberg et al. 2013). Low coverage for variant calling and limited copy 
number analysis might explain these results that deviate from the more generally believed 
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hypothesis that different foci have a common origin. This was also confirmed by other studies using 
copy number changes.  
For the development of correct DNA diagnostics, it will hence be necessary not only to study more 
matched primary-metastatic tumor pairs, but also to sample multiple separate tumor foci from 
within the same prostate. This should help to determine the molecular events that can occur during 
progression to advanced disease or alternatively may even help to identify less aggressive lesions.  
 
1.2.3.2. Single nucleotide polymorphisms (SNPs) 
The risk of developing PCa doubles for men with a first-degree relative affected by PCa and increases 
further with more affected relatives (Goh et al. 2012). This indicates that PCa is one of the most 
heritable cancers with up to 15% of cases linked to family history (MacInnis et al. 2010). Twin studies 
similarly suggest that up to 42% of the risk for developing PCa is linked to heritable components, 
indicating that the contribution of genetic factors to the development of PCa is greater than to the 
development of other types of common human tumors (Lichtenstein et al. 2000).  
Genome-wide association studies (GWAS) compare the frequency of common single nucleotide 
polymorphisms (SNPs) throughout the entire genome (minor allele frequency > 1-5% in the 
population) in PCa patients and controls. In a typical GWAS, up to one million SNPs are evaluated in 
large cohorts of thousands of patients versus controls to determine the link between specific forms 
of the SNPS and the probability to develop PCa. Because only 1 or 2 million of approximately 50 
million SNPs are assessed, the SNPs associated with PCa through GWAS are unlikely to be the causal 
genetic risk variant. However, these risk-associated SNPs are to segregate with the underlying causal 
variant since they are in linkage disequilibrium (Zhang et al. 2012). More than 70 PCa susceptibility 
loci explaining approximately 30% of the familial risk have been identified (Choudhury et al. 2012, 
Eeles et al. 2013). Additional case-control studies are generally needed to confirm the GWAS 
findings, as the risk of false positives is appreciable. The relative increased risk of developing the 
disease based on any single polymorphism discovered to date is small, generally < 1.5-fold, but risk 
increases with increasing number of risk alleles carried. A recent study evaluated 25 000 PCa cases 
and identified 23 novel PCa susceptibility loci (Eeles et al. 2013). Pathway enrichment of previously 
and newly reported susceptibility regions revealed overrepresentation in pathways regarding cell 
adhesion and extracellular matrix and transcriptional regulation by the AR (Eeles et al. 2013). 
Prospective GWAS studies can also evaluate rarer variants (minor allele frequency ≤ 1%) associated 
with PCa risk which may be more highly penetrant and carry higher relative risk. 
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The SNP risk markers can be located within protein-coding genes, in intergenic regions, in 
unannotated transcripts such as lncRNAs or miRNAs, in regulatory regions or in loci without any 
known genes at all. There are several potential mechanisms by which these SNPs may be associated 
with altered PCa risk, including genetic linkage to a coding variant in a cancer-relevant gene, changes 
in promoter or enhancer binding sites, changes in chromatin structure that affects expression of 
adjacent or distant genes, or changes in expression of noncoding RNAs (Choudhury et al. 2012).  
The 8q24 region contains various independent PCa-susceptibility loci within a 1 Mb segment, and 
some of them were found to be significantly associated with other types of cancer as well, including 
colorectal, breast, ovarian and bladder cancer. Surprisingly, no gene has been annotated in this 1 Mb 
region, and its biological significance in cancer remains unclear. A possible explanation is the 
presence of an enhancer which physically interacts with the MYC oncogene in a tissue-specific 
manner (Ahmadiyeh et al. 2010). Similarly, the rs8072254 and rs1859961 SNPs within the 17q24 
region are associated with PCa risk and modulate AR and AP-1 binding respectively, leading to an 
increased transcriptional activity of the prostate-specific enhancer in this block that loops to the 
SOX9 oncogene (Zhang et al. 2012).  
Multiple SNPs in the promoter region of KLK3 have been associated with serum PSA levels and some 
have been suggested to be associated with risk of PCa (Cramer et al. 2003, Severi et al. 2006). Very 
recently, a SNP in the intronic region of the TERT gene at 5p15 was identified that is associated with 
TERT expression (Kote-Jarai et al. 2013). These studies demonstrate the potential interaction 
between genetic variants and clinical outcome.  
Subjects participating in most of the GWAS studies were recruited from the general population, and 
thus primarily represent sporadic cancer cases. A study of SNPs in hereditary PCa indicated that at 
least a subset of PCa risk-related loci identified by case-control GWAS are also associated with 
disease risk in hereditary PCa (Jin et al. 2012). Several GWAS studies revealed associations of 
rs11672691, rs6497287 and rs1571801 with more aggressive disease, which might make them useful 
as prognostic markers (Amin Al Olama et al. 2013, Duggan et al. 2007, FitzGerald et al. 2011).  
Although GWAS studies have revealed interesting aspects of PCa, the potential benefits of applying 
risk models based on SNPs in clinical practice are difficult. In the future, however, these genetic 
markers could be incorporated in clinical decision making and take part in risk models, screening 
paradigms and treatment recommendations.  
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1.2.4. DNA methylation 
Epigenetics is the study of heritable changes in gene expression caused by mechanisms other than 
those inherited via the underlying DNA sequences. Here, we focus on DNA hyper- and 
hypomethylation of cytosine-guanine (CpG) islands. DNA methylation can lead to gene-silencing 
either by inhibiting the access of target binding sites to the transcriptional activators or by promoting 
the binding of methyl-binding domain proteins, which interact with histone deacetylases that 
promote chromatin condensation into transcriptionally repressive conformations (Majumdar et al. 
2011).  
In general, overall DNA hypomethylation increases during tumor progression, while the specific 
hypermethylation of promoter regions of tumor suppressor genes is observed in both initiation and 
progression of PCa (Yegnasubramanian et al. 2008). The best characterized gene of which the 
promoter is hypermethylated in more than 90% of PCas encodes the glutathione S-transferase P1 
(GSTP1) gene (Lee et al. 1994). More than 60 genes have been reported to be differentially 
hypermethylated in progressive PCa (Majumdar et al. 2011). Again, some of these genes have been 
shown to be involved in the androgen signaling pathway. Recently, the tumor suppressor miR-124 
targeting the AR has been shown to be silenced by methylation in clinical PCa samples (Shi et al. 
2012). An example of a hypomethylated gene is the plasminogen activator urokinase gene. Its 
increased expression is associated with higher invasive capacity of PCa cells in vitro and increased 
tumorigenesis in vivo (Majumdar et al. 2011).  
Earlier epigenetic studies focused on individual or small numbers of genes. The advent of next-
generation sequencing now allows profiling of methylomes, defined as the total of all DNA 
methylations in the whole genome. For PCa, such genome-wide studies revealed hypermethylation 
of homeobox or T-box genes, the FLT4, AOX1 and WFDC2 gene and dysregulation of genes involved 
in TNF--dependent apoptosis (Kim et al. 2011a, Kim et al. 2012, Kim et al. 2011b, Kobayashi et al. 
2011, Kron et al. 2009). Similar to the CNA conservation, the unique DNA methylation signature of 
the tumor/metastasis-initiating focus was shown to be closely maintained during metastatic 
dissemination (Aryee et al. 2013). The alterations in DNA methylation patterns that are associated 
with phenotypic changes in gene expression have a surprising strong tendency to be maintained 
within metastases in an individual patient (Aryee et al. 2013).  
Methylome analysis of 51 primary PCas identified 147 000 cancer-associated epigenetic alterations, 
of which 58% were hyper- and 42% hypomethylated (Borno et al. 2012). Tumors without the 
TMPRSS2-ERG fusion contain more differentially methylated regions than fusion-positive tumors, 
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suggesting a more pronounced role for epigenetic mechanisms in fusion-negative tumors (Borno et 
al. 2012).  
Clearly, in combination with DNA mutations and gene fusions, DNA methylation markers hold great 
promise as clinically useful diagnostic or prognostic parameter. One major open question is whether 
specific subtypes of the disease might be identified by combinations of hyper- and hypomethylation 
events. This is one of the topics that might be answered by more comprehensive, genome-wide 
studies.  
 
1.2.5. Non-coding RNAs 
1.2.5.1. MicroRNAs 
MicroRNAs are small, non-coding RNA molecules that bind to the 3’ untranslated region (UTR) of 
mRNA. This binding effectively silences translation by blocking access to the ribosome or by marking 
the target mRNA for degradation. Genes encoding miRNAs are found as independent entities or 
within introns of other genes, within repetitive genomic elements or within transposable element 
sequences.  
At present, more than 100 miRNAs have been reported to be deregulated in PCa. There are however 
many conflicting results in the literature which is likely due to the still immature technology to 
capture and quantitate miRNAs and the contamination of normal cells in the tumor samples 
(Carlsson et al. 2011, Fuse et al. 2012, Sun et al. 2009, Volinia et al. 2006). Despite these 
inconsistencies, all studies confirm the widespread dysregulation of miRNAs in PCa. Moreover, a 
subset of these have been experimentally shown to be involved in the initiation, progression from 
androgen-dependent to androgen-independent stage, invasion and/or metastasis of PCa (reviewed 
in (O'Kelly et al. 2012)). A growing number of miRNAs is being identified as interfering with the AR 
pathway. A gain-of-function screen in PCa cell lines identified 13 unique miRNAs that influence the 
level of AR in these cells (Ostling et al. 2011). On the other hand, androgens control the up-regulation 
of miR-125, miR-21 and miR-141 and consequently the down-regulation of their respective target 
mRNAs (Ribas et al. 2009, Shi et al. 2007, Waltering et al. 2011).   
Oncomirs are miRNAs that are dysregulated in cancer. Examples of miRNAs that show decreased 
expression in PCa compared to normal prostate tissue are miRNA-143, -145 and -200. The mRNA 
targets for these miRNAs are being discovered, and it seems that the miRNA down-regulation results 
in epithelial-to-mesenchymal transition and enhanced tumor cell invasion and migration (Gregory et 
al. 2008, Korpal et al. 2008, Peng et al. 2011). Conversely, miRNAs that show increased expression 
are miRNA-21 and miRNA-125b as they play important roles in resistance to apoptosis (Lee et al. 
Introduction 
 
19 
 
2005, Li et al. 2009c). Here too, although some downstream mRNA targets are being discovered, 
most of them remain poorly understood. So far, many studies examining the role of miRNAs are 
associative and rely on PCa cell lines as surrogates for clinical response. It is thus envisaged that the 
focus will shift towards clinically relevant studies both in animals and humans to provide a better 
understanding of the working mechanisms of miRNAs (O'Kelly et al. 2012). Alternatively, studies in 
humans could pinpoint those microRNAs that can be used as a prognostic marker. In this way, miR-
221 was discovered to be progressively down-regulated in primary PCa and metastasis (Spahn et al. 
2010). This down-regulation is associated with Gleason score, tumor progression and clinical 
recurrence during follow-up (Spahn et al. 2010).  
Interestingly, certain microRNAs are not only elevated in the prostate tumor, but also in the 
circulation (for example in the exosomes) of the patient, suggesting they act similar to hormones and 
might play a role in priming the site of metastasis. An example is the up-regulation of miR-375 which 
can predict biochemical relapse, with high expression being associated with an unfavorable outcome 
(Selth et al. 2012). Circulating miRNAs open up the possibility of their development into diagnostic 
tools. Ultimately, miRNAs could be used to predict outcome and response to treatment or even be 
targets of treatment themselves.  
 
1.2.5.2. Long non-coding RNAs (lncRNAs) 
LncRNAs share common traits with mRNA because they are mostly transcribed by RNA polymerase II, 
they are capped, polyadenylated and spliced but they do not contain an open reading frame. Most of 
the lncRNAs identified to date display overexpression in PCa samples. A few lncRNAs seem to be 
prostate-specific: PCA3/DD3, PCGEM1, PRNCR1 and PlncRNA-1. 
The best documented is PCA3 which was discovered as a differentially expressed RNA (DD3). It is 
expressed exclusively in the prostate, is highly overexpressed in PCa and detectable in urine samples 
of PCa patients (Bussemakers et al. 1999). PCA3 has been conclusively shown to be a better 
biomarker for PCa in biopsy samples than PSA. PCA3 and PSA together are an even better predictor 
of PCa (Wang et al. 2009). This led to the FDA approval of a PCA3 urine test as diagnostic aid to 
decide on repeated biopsy testing. 
Other lncRNAs are still in the early discovery phase. PCGEM1 also encodes an androgen-regulated 
lncRNA that is expressed exclusively in glandular epithelial cells of both normal and tumor specimens 
of human prostate (Srikantan et al. 2000). In patients, tumor-associated overexpression of PCGEM1 
was detected in 84% of the samples (Srikantan et al. 2000). Probably the least characterized lncRNA 
is PRNCR1 (prostate cancer non-coding RNA 1), an approximately 13 kb intron-less non-coding RNA 
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transcribed from the 8q24 region (Chung et al. 2011). In a small cohort, the PRNCR1 expression was 
up-regulated in half of the PCa samples as well as in the precursor PIN lesion. Finally, PlncRNA-1 was 
found to be overexpressed in 11 out of 16 PCa samples and a knockdown resulted in decreased cell 
viability, increased apoptosis and a decrease of AR mRNA and protein (Cui et al. 2013). 
Transcriptome analyses of a cohort of 81 prostate tissues led to the discovery of 121 unannotated 
PCa-associated lncRNA transcripts (PCATs). Similar to the gene signatures, changes in the levels of 
these transcripts are being studied for their use as diagnostic tool. In a first study, their expression 
levels accurately discriminate benign, localized tumor and metastatic prostate samples (Prensner et 
al. 2011). One of these transcripts, PCAT-1, seems to be a prostate-specific transcriptional repressor 
that regulates cell proliferation and that may hence have an important role in PCa progression 
(Prensner et al. 2011). Similar approaches might contribute to identify additional disease-associated 
lncRNAs that may further improve the stratification of cancer subtypes.  
 
1.2.6. A role of AR in PCa 
It stands without debate that the AR protein is a crucial transcription factor in normal as well as 
diseased prostate, and that it plays a pivotal role both during development and progression of PCa. 
As a transcription factor, it controls proliferation as well as differentiation of prostate cells by 
regulating processes at multiple levels (proteins, miRNAs and lncRNAs) (Balk et al. 2008). The AR 
gene itself is a target for (de-)methylation, amplification and mutagenesis that lead to gain of 
function. Many of the events described above not only affect the AR gene itself, but the entire 
pathway, for example by disturbing AR cofactors. Since its dramatic effects on chromatin structure, 
the AR is now also a prime suspect to play a role in many of the genomic events like translocations. It 
is even becoming more and more clear that part of the genetic predisposition to PCa also involves 
the AR at some level, for example through the effect of SNPs on androgen-response (Clinckemalie et 
al. 2013). All these processes are illustrated in Figure 1.4. 
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Figure 1.4. The genomic landscape of PCa. The integrated analysis of DNA, RNA and methylation data 
obtained with next-generation sequencing will help elucidate all relevant (epi)genetic changes in 
cancers (inner). Involvement of the androgen receptor in PCa tumorigenesis and progression can be 
demonstrated at all levels (outer).  
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1.3. CELL LINES AS MODEL FOR PROSTATE CANCER  
1.3.1. Use of different prostate cancer cell lines 
Recently, a debate is ongoing about the relevance of cell lines: are they or are they not 
representative of the original tumor? To what extent do the cells actually resemble their tissue of 
origin after years in culture? Nevertheless, cell lines still play an essential role in biomedical research 
as they are cheap and ensure sufficient material for long-term use. Despite numerous attempts to 
obtain PCa cell lines, only a handful of human PCa cell lines have been generated, of which the most 
commonly used were isolated from metastatic lesions rather than primary tumors (Table 1.3). 
Moreover, each model system displays its own characteristics.  
 
Table 1.3. Overview of the PCa cell lines that will be used in this doctoral thesis.  
Name Origin AR protein PSA protein References 
C4-2B Bone metastasis of LNCaP 
in nude mice 
Mutated Positive (Thalmann et al. 1994) 
CWR22Rv1 Xenograft from primary PCa Mutated Positive (Sramkoski et al. 1999) 
DU145 Brain metastasis Negative Negative (Stone et al. 1978) 
LNCaP Lymph node metastasis Mutated Positive (Horoszewicz et al. 1980) 
PC-3 Vertebra metastasis Negative Negative (Kaighn et al. 1979) 
VCaP Vertebra metastasis Wild type Positive (Korenchuk et al. 2001) 
 
The first human PCa epithelial cell lines to be established were LNCaP, PC-3 and DU145. Even now, 
these three cell lines and their derivative sublines are still used in the majority of studies. As PC-3 and 
DU145 cells do not express significant levels of AR and PSA, they cannot be used to study androgen 
signaling or castrate-sensitivity. Although LNCaPs are androgen-responsive and produce PSA, they 
express a mutated AR (T877A), which results in broader ligand-specificity (Veldscholte et al. 1990). 
LNCaP and C4-2B cells represent a progression model that mimics advancing disease from poorly 
tumorigenic, non-metastatic in LNCaP, to metastatic and castration-resistant in C4-2B.  
A brain metastasis with moderately differentiated adenocarcinoma gave rise to the DU145 cells. The 
PC-3 cells were established by using poorly differentiated metastatic tumor tissue from a lumbar 
vertebra. Both patients had previously been castrated as treatment for the PCa. 
More recently, novel cell lines have been established, among which the VCaP cell line. These cells 
were derived from a vertebral bone metastasis from a man with hormone refractory PCa (Korenchuk 
et al. 2001). The tissue was first heterotransplanted into immune-deficient mice and later harvested 
for in vitro culture. These androgen-sensitive cells express higher levels of wild type AR than LNCaP 
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cells. Moreover, they harbor the TMPRSS2-ERG fusion, which makes them an appropriate system to 
investigate the functional significance of this rearrangement (Perner et al. 2006).  
CWR22 cells have been propagated from an epithelial xenograft derived from a primary prostate 
carcinoma from a patient with osseous metastases. CWR22R is a relapsed xenograft from castrated 
mice carrying the androgen-dependent CWR22. Also, the CWR22Rv1 cell line is the first variant of 
CWR22R cells that could be propagated in cell culture (Sramkoski et al. 1999). 
 
1.3.2. Development of LNCaP cells 
LNCaP cells were grown out of small tissue fragments obtained by needle aspiration biopsy of a 
metastatic lesion in the left supraclavicular lymph node of a 50-year-old Caucasian male 
(Horoszewicz et al. 1980). This patient suffered from a rapidly progressing PCa with minimal and 
temporary response to hormonal therapy and no response to chemotherapy.  
The patient was diagnosed with a moderately differentiated PCa based on needle biopsy of the 
prostate and retroperitoneal lymph node exploration. Treatment with oral estrogens could not 
prevent the development of bone metastases six months after diagnosis. Castration only resulted in 
a mild and temporary response since the patient presented with a hard enlarged prostate and pain in 
his right flank five months after castration. One month after the start of chemotherapy, a needle 
biopsy was taken from a palpable left supraclavicular lymph node which was the source of LNCaP 
cells. Finally, 18 months after diagnosis, the patient died.  
The LNCaP cells express many of the prostate-specific genes and are AR positive. For this reason, it 
has been used in many preclinical studies. Several sublines of these LNCaP cells, among which the  
C4-2B cells, were established to represent CRPC.  
 
1.3.3. Development of C4-2B cells 
The C4 subline was derived through the coinoculation of two cell lines: one million LNCaP cells were 
injected subcutaneously into a male athymic nude mouse, together with one million cells of the 
human osteosarcoma cell line MS. The host was castrated 8 weeks after injection and a single tumor 
specimen was excised 4 weeks later. This specimen was used as the source for the generation of a 
second generation cell line, C4-2, maintained for 12 weeks in a castrated host after subcutaneous 
injection together with the MS fibroblasts. Finally, C4-2 cells were inoculated orthotopically in a 
castrated mouse. At the time when metastases were detected, the mouse was sacrificed and tumor 
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tissue was harvested from the bone for subsequent derivation of the C4-2B subline (Thalmann et al. 
1994). A schematic overview of the entire process can be found in Figure 1.5. 
 
Figure 1.5. The development of LNCaP and C4-2B PCa cell lines. LNCaP cells were isolated from a 
supraclavicular lymph node metastasis. The C4-2B cell line is derived from a LNCaP tumor grown in 
castrated mice. Intact and castrated mice are represented in dark and light gray respectively. A dark 
syringe represents subcutaneous injection of PCa cells with human fibroblast. A light syringe 
indicates orthotopic injection of PCa cells only.  
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CHAPTER 2: 
AIMS OF THIS STUDY 
Cancer cell lines are commonly used as laboratory resources to study basic molecular and cellular 
biology. For PCa, LNCaPs are the most commonly used cells, as they have been cited in over 6200 
papers (number of Pubmed hits with the term ‘LNCaP’ in March 2014). However, the interpretation 
of experiments on these cells is hampered by the absence of a known mutational status of the genes 
involved. The first aim of this project was therefore to provide an extensive database of genetic 
variations in the exome of LNCaP cells. We focused on missense and nonsense single nucleotide 
variants (SNVs) and short insertions and deletions (indels). We also tried to answer the question 
whether different LNCaP cell lines which are known to be quite variable between laboratories, are 
genetically unstable, heterogenous and/or heterozygous.  
The LNCaP/C4-2B progression model mimics the phenotypic and genotypic changes often observed 
in PCa patients when evolving from androgen-sensitive to metastatic, castration-resistant PCa. The 
second aim was to characterize both LNCaP and C4-2B cell lines more thoroughly. We therefore 
performed exome and transcriptome sequencing, from which we could derive SNVs and differential 
expression patterns. Based on these results, we tried to detect some molecular differences that 
could explain the increased metastatic capacity of the C4-2B cells. In addition, these analyses were 
used as training for aim 3. 
PCa is a very heterogeneous disease, ranging from indolent to very aggressive tumors. It still remains 
a clinical challenge to differentiate both forms of PCa. A better molecular profiling of the tumors 
should enable a better classification of the disease, should unveil the signaling pathways that are 
involved in the carcinogenesis and ultimately could provide information that could direct a more 
personalized treatment. One approach in doing so is to study the contribution of somatic base pair 
substitutions to the oncogenic process. At the onset of this study little was known about PCa 
mutations. In the meantime, several reports have been published. However, new substitutions are 
discovered with almost every new case that is analyzed. The third aim of this project was therefore 
to perform whole exome sequencing of tumors from high-risk PCa patients and identify the tumor-
specific SNVs and hence the genes that are disrupted. The tissues were collected within the frame of 
the PEARL (ProstatE cAncer Research team Leuven) consortium. Finally, the functional consequences 
of some of the SNVs have been studied, together with their potential influence on the initiation 
and/or aggressiveness of PCa. This would then result in a deeper insight in the developmental 
mechanisms of PCa. 
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The work presented in this chapter has been conducted by the PhD candidate.  
 
 
3.1. ABSTRACT 
Background. The LNCaP cell line is widely used as a model for prostate cancer. However, information 
on protein-changing mutations, genetic heterogeneity and genetic (in)stability is largely lacking for 
these cells.  
Methods. Next-generation sequencing of the LNCaP exome revealed many single nucleotide variants 
(SNVs). To help identify the mutations that are most likely drivers of the oncogenic process, we 
developed an in silico protocol, which can be adapted for other exome analyses. 
Results. We detected 1802 non-synonymous SNVs and 218 small insertions and deletions in the 
LNCaP exome. We confirm the known mutations in the androgen receptor and the PTEN gene, but 
most other mutations remained undescribed until now. The presence of 38 out of 42 SNVs was 
confirmed in monoclonal as well as in polyclonal LNCaP derivatives. Moreover, most variants were 
also detectable in LNCaP mRNA. 
Conclusions. We provide an extensive database of genetic variations in the protein-coding part of the 
genome of LNCaP cells, which should be taken into consideration when using LNCaP cells or its 
derivatives as models for prostate cancer. From the analysis of several LNCaP derived cultures and 
clones, we can confirm that the cell line is heterozygous for a large number of variants and that both 
the variant and the wild type allele can be simultaneously expressed as mRNA. The fact that the SNVs 
in the E-cadherin, CDK4, Notch1 and PlexinB1 genes are absent in some of the subclones strongly 
indicates a degree of genetic instability.  
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3.2. INTRODUCTION 
The LNCaP PCa cell line was derived from a biopsy taken from a lymph node of a fifty-year-old 
Caucasian male with metastasized PCa (Horoszewicz et al. 1980). These androgen-sensitive cells have 
been used in work leading to at least 5000 publications over the last three decades and are the most 
frequently used in vitro model for basic as well as preclinical studies of PCa. A wide range of 
biological information such as its transcriptome, karyotype and limited analyses of mutations has 
been reported (Bainbridge et al. 2006, Pan et al. 1999, van Bokhoven et al. 2003). However, to our 
knowledge, there are no data available on the exome or the complete exon content of these LNCaP 
cells.  
Here, we re-sequenced the complete exome of the LNCaP PCa cells with the aid of next-generation 
sequencing, in search for mutations that lead to amino acid substitutions or to small exonic 
insertions and deletions. We have tested the quality of our data by re-sequencing genomic PCR 
products encompassing over 40 exons. The mutations will be discussed in light of the recently 
reported genomic data on PCa (Berger et al. 2011b, Kumar et al. 2011, Robbins et al. 2011, Taylor et 
al. 2010). To determine which of the mutations would be the best candidate driver mutations, we 
developed an in silico prediction algorithm which could be useful for the analyses of (prostate) 
cancer genomic data.  
The biological characteristics of the LNCaP cells, like for many other cell lines, are known to vary 
between different laboratories or even between different time points during culture (Esquenet et al. 
1997). It is unknown whether these differences are due to heterogeneities within the cell line, 
phenotypic changes like adaptations to different culture settings, or to genotypic drift by relatively 
high mutation rates combined with culture-induced selection. We will discuss these possibilities by 
verifying the presence of a subset of the SNVs and SNPs in LNCaP cultures from different origins.  
 
 
3.3. MATERIALS AND METHODS 
3.3.1. Cell culture 
Cell lines (LNCaP, PC-3, DU145, VCaP and CWR22Rv1) were obtained from the American Type Culture 
Collection. LNCaP (UK) and LNCaP TR2 were kindly provided by Dr. C.L. Bevan (Imperial College, 
London, UK). LNCaP (NL) and C4-2B were obtained from Dr. J. Trapman (Josephine Nefkens Institute, 
Erasmus University Medical Centre, Rotterdam, The Netherlands) and Dr. M.R. Stallcup (University of 
Southern California, LA, CA, USA) respectively. The passage number of the LNCaP cells, LNCaP (UK) 
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and C4-2B cells is 48, 12 and 42 respectively. LNCaP, C4-2B and CWR22Rv1 PCa cells were grown in 
Roswell Park Memorial Institute medium (RPMI, Gibco, Invitrogen, Gent, Belgium) containing 2 g/l 
glucose supplemented with 10% heat-inactivated fetal calf serum (FCS). VCaP cells were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco) with 4.5 g/l glucose. DU145 cells were grown in 
DMEM containing 10% FCS and 4 µg/ml insulin. PC-3 cells were grown in Ham’s F12 (Gibco)/DMEM 
(1:1) supplemented with 10% FCS. All cells were grown at 37°C and 5% CO2 and media were 
supplemented with 100 µg/ml streptomycin and 100 µg/ml penicillin.  
 
3.3.2. DNA isolation and whole-exome capture sequencing 
High-molecular weight DNA was extracted from cultured LNCaP cells using the GenElute Mammalian 
Genomic DNA Miniprep Kit (Sigma-Aldrich, Bornem, Belgium). The DNA was further purified using 
ethanol precipitation with ammonium acetate. The concentration was quantified using a Nanodrop 
(Thermo Fisher Scientific, Erembodegem-Aalst, Belgium), Quant-iT PicoGreen (Invitrogen) and 
Bioanalyzer (Agilent Technologies, Diegem, Belgium). Five microgram of DNA was fragmented using 
an ultrasonic solubilizer (Covaris, KBiosciences, Utrecht, The Netherlands) (10% duty, intensity of 5 
with 200 cycles per burst for 180s) for the construction of a 200 base pair fragment DNA library. 
Whole-exome capture was performed using the SureSelect Human All Exon System (Agilent 
Technologies) according to the manufacturer’s instructions. We generated 100 base pair long paired-
end reads using the GAIIx sequencer (Illumina, Eindhoven, The Netherlands). We used one lane of a 
flow cell for the sample. The produced image data were converted to intensity files and were 
processed through the Firecrest and Bustard algorithms provided by Illumina to call the individual 
sequence reads.  
 
3.3.3. Bioinformatics: Sequence alignment, removal of PCR duplicates and detection of SNVs and 
indels 
Quality control was performed using FastQC software (version 0.4) 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/). Paired-end reads were aligned to the 
human reference genome (hg19, NCBI Build 37) using Bowtie (version 0.12.4) and Burrows-Wheeler 
Aligner (BWA) (version 0.5.6) (Langmead et al. 2009, Li et al. 2009a). Processing of the aligned reads 
was done using SAMtools (version 0.1.7) (Li et al. 2009b). Because there were duplicated reads which 
were generated during the PCR amplification process, paired-end reads that aligned to the same 
genomic positions were removed using Picard (version 1.22) (http://picard.sourceforge.net/).  
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To detect SNVs, we used the VarScan program (version 2.1) with default parameters (Koboldt et al. 
2009). Variant calls were filtered according to different criteria using the Galaxy website (see Results) 
(Blankenberg et al. 2010, Goecks et al. 2010). For the detection of indels, we used the Dindel 
software (version 1.01) (Albers et al. 2011). Default options were used, together with the criterion 
that each candidate indel had to be seen in at least two supporting reads. Reads were visualized with 
Integrative Genomics Viewer (IGV, version 1.4.2) (Robinson et al. 2011), while SNVs and indels are 
represented in a Circos plot (version 0.52) (Krzywinski et al. 2009). BEDtools (version 2.6.1) was used 
to calculate coverage information (Quinlan et al. 2010).  
 
3.3.4. In silico prediction of impact of SNVs on protein function 
Ranking A is a combination of the predictions of three independent software programs (SIFT, 
PolyPhen2, and MutationAssessor) (Adzhubei et al. 2010, Kumar et al. 2009, Reva et al. 2011). Each 
of these programs uses different calculations which result in an internal score that reflects the 
probability that an amino acid change will be accepted at a given position of a protein sequence. We 
therefore first normalized the internal score of MutationAssessor to values between 0 and 1, and 
took the complement of the SIFT probability as the normalized score of this tool. The average of the 
three normalized scores resulted in Ranking A. Ranking B was obtained using the Endeavour software 
and includes functional and pathway annotations, protein-protein interactions, expression levels and 
literature (Tranchevent et al. 2008). We used two different training sets for Endeavour. A first one is 
the KEGG pathway for PCa. A second one is a list of 115 genes that we found in literature to be 
involved in PCa (development). Again, the result of both training sets was combined to obtain one 
Ranking B. Both Ranking A and B assign a rank to each gene. By averaging both ranks, we obtained 
the final ranking.  
 
3.3.5. Sanger sequencing to validate non-synonymous substitutions 
Primers for validation were designed by targeting regions immediately flanking the predicted variant 
using the NCBI Primer-Blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and obtained from 
Integrated DNA Technologies (Haasrode, Belgium). Polymerase chain reactions were performed 
following standard protocols using Taq DNA polymerase (Fermentas GmbH, Thermo Fisher Scientific). 
Products were run on an agarose gel and assessed for purity and size. The remaining products were 
purified using the GeneJet PCR Purification kit (Fermentas GmbH). Sanger sequencing was performed 
at LGC Genomics. Sequence trace files were analyzed using Chromas Lite.  
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3.4. RESULTS 
We performed an exome re-sequencing study of the LNCaP PCa cell line. Exonic fragments were 
enriched from sonicated genomic DNA using Agilent’s SureSelect technology for targeted exon 
capture, which targets 37 Mb of sequences from exons and their flanking regions in ~20000 genes. 
Sequencing with the Illumina GAIIx platform resulted in 25348495 raw 100 base pair long, paired-end 
reads (5.07 Gb of sequence). These reads were then aligned to the human reference genome (build 
37) using BWA and Bowtie (see Methods) (Langmead et al. 2009, Li et al. 2009a).  
 
3.4.1. Detection and filtering of SNVs 
On average, 93% of all exonic nucleotides in the SureSelect kit (target regions) were covered with at 
least one sequencing read, while 78% of these nucleotides were covered at least 12 times, the latter 
of which was used as a cutoff in our further analyses. The average sequencing read depth is 43x in 
target regions. Using the Bowtie or BWA aligner followed by the VarScan software, 193595 and 
306844 SNVs were predicted, respectively (Koboldt et al. 2009, Langmead et al. 2009, Li et al. 2009a). 
All the variant calls were filtered using a combination of criteria that reduced the likelihood that a 
sequencing error was identified as a single nucleotide variant (Table 3.1). These filtering criteria 
required that at least 12 reads covered a potential variant, that all reads had a Phred-quality score of 
at least 30 and that the frequency of the non-reference allele was at least 30%. Variants passing 
these filters were annotated by Ensembl using the Perl API. We further selected those SNVs that fall 
into protein-coding regions and would result in a change of the amino acid sequence. Mapping to 
dbSNP (version 131) allowed us to separate known SNPs from de novo variants. We could not 
determine which of the remaining SNVs were somatic or tumor-specific, since no matched normal 
tissue from the corresponding patient is available. Next, the remaining SNVs were investigated to 
remove all strand biases as these are potential sequencing errors. Finally, only SNVs that were found 
after alignment with Bowtie as well as with BWA were taken into consideration. Using this approach, 
1685 non-synonymous coding SNVs and 117 SNVs that introduce a stop codon in protein-coding 
regions were found in 1610 different genes (Table 3.1). Of these, only 98 SNVs or 5.4% are 
homozygous (with a mutation allele frequency of at least 70%). We observed a ratio of non-
synonymous to synonymous changes of 2.1:1, which is not higher than the ratio of 2:1 predicted for 
non-selected passenger mutations (Bardelli et al. 2003).  
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Table 3.1. Filters used to identify point mutations in the LNCaP exome 
Number of SNVs BWA Bowtie 
Predicted 306 844 193 595 
With ≥ 12x coverage 286 603 177 179 
With ≥ 30 Phred-quality 203 710 130 941 
With ≥ 30% mutation allele frequency 48 788 42 346 
In coding regions 17 567 17 211 
Non-synonymous coding or gained stop codon 8 900 8 671 
Not present in dbSNP131 1 997 1 987 
Without strand bias 1 957 1 959 
In common 1 802 
Mutation allele frequency denotes the number of reads containing the mutation 
divided by the total number of reads. The list of SNVs is available upon request.  
 
 
Figure 3.1. Mutation spectrum of single nucleotide substitutions. Percentages of mutations in each of 
the six possible mutation classes.  
 
3.4.2. Nucleotide substitution frequencies  
The predominant nucleotide substitutions seen in SNVs of the LNCaP exome are transitions of A <-> 
G or C <-> T (Figure 3.1). Particularly, we observed that 61.4% of our SNVs are transitions, while 
38.6% are transversions, a 1.6:1 ratio. Such a mutation spectrum, which is dominated by C-to-T/G-to-
A transitions, has been noted in several other adult cancers such as melanoma, breast, lung, 
colorectal and ovarian cancers as well as in PCa (Greenman et al. 2007, Kumar et al. 2011).   
Besides the non-synonymous coding variants, other variants were detected as well. Table 3.2 depicts 
the intragenic locations of the SNVs and the consequence of these variants for the open reading 
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frames (gain or loss of stop codon, whether or not there is a change in coding sequence). About 22% 
of all novel variants found after filtering were single-base substitutions that were non-synonymous 
coding. Only 1.7% of variants result in stop codons, and 8.6% of the variants result in alterations of 
untranslated regions immediately adjacent to the start and stop codons.  
 
Table 3.2. Mutations identified in LNCaP cells   
Type of change  Novel SNVs Known SNPs 
Non-synonymous coding 1 802 6 823 
Synonymous coding  923 7 744 
Stop gained  134 63 
Stop lost  4 17 
Within non-coding gene  1 702 10 244 
Intronic  2 851 19 242 
3 prime UTR  456 2 564 
5 prime UTR  244 1 267 
Abbreviation: UTR, untranslated region 
 
 
3.4.3. Detection of small insertions and deletions 
For the prediction of small (< 7 base pairs) insertions and deletions, we used the Dindel software 
(Albers et al. 2011) resulting in 43767 indels. These indel calls were filtered using a combination of 
criteria (Table 3.3). With the requirement that the Phred-quality was at least 20, we detected 17155 
events of which 8014 (47%) were not previously documented in dbSNP131. Further filtering for 
indels in coding regions and by strand bias, resulted in 218 indels of which 67 were insertions and 
151 deletions. All indels that were found in the LNCaP exome were heterozygous with mutant allele 
frequencies below 70%. It should be noted that the frameshift in the PTEN gene (Vlietstra et al. 1998) 
was also detected in our data. Figure 3.2 depicts a Circos-plot with an exome-wide representation of 
all novel homozygous and heterozygous SNVs as well as small insertions and deletions that were 
found in the exome of the LNCaP cell line.  
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Table 3.3. Filters used to identify indels in the LNCaP exome 
Filtering criteria  Number of indels 
Predicted  43 767  
With Phred-quality ≥ 20  17 155  
Not present in dbSNP131  8 014  
Change in amino acid sequence  223 
Without strand bias  218 
 
 
Figure 3.2. The catalogue of mutations in LNCaP cells. Figurative representation of the catalogue of 
mutations in the exome of LNCaP cells. Chromosome ideograms are shown around the outer ring and 
oriented pter-qter in a clockwise direction with centromeres indicated in red. Other tracks contain 
alterations (from outside to inside): 1704 heterozygous SNVs shown by density per 10 megabases 
(dark red bars); 98 homozygous SNVs (light red rectangles), 151 deletions (outer blue rectangles) and 
67 insertions (inner blue rectangles).  
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3.4.4. Prediction of impact on protein function 
The high number of identified SNVs obstructs a straightforward analysis of their effects on protein 
functions and the identification of their role in oncogenesis. However, we wanted to determine the 
effects of the non-synonymous SNVs identified in our LNCaP cells on the structure and function of 
the changed proteins. We developed a workflow to calculate a score for the theoretical impact of 
each SNV. 
We first used publicly available software to make in silico predictions of the impact that these SNVs 
could have on protein structure and/or protein function. These predictions were calculated by three 
different software packages: SIFT, PolyPhen2 and MutationAssessor (Adzhubei et al. 2010, Kumar et 
al. 2009, Reva et al. 2011). Only 7% of the mutations were predicted by all three methods to have a 
potential functional effect, whereas 26% of the mutations were predicted to be potentially 
deleterious by at least one of the three methods. We next focused on those variants for which all 
three programs predicted an impact and combined these predictions into one ranking (Ranking A in 
Figure 3.3).  
 
 
Figure 3.3. Prioritization workflow. SIFT, PolyPhen2 and MutationAssessor are in silico software 
programs that predict the potential influence a SNV might have on protein function. All three 
predictions were combined into ranking A. Gene information such as annotation, protein-protein 
interaction and expression data was used to generate ranking B. The combination of ranking A and B 
results in a final ranking that prioritizes the mutated genes and can help in defining genes for future 
research.  
 
To take into account additional information about the genes in which SNVs are localized, we used the 
Endeavour software (Tranchevent et al. 2008). This approach allowed us to include data on 
functional and pathway annotation (GO, KEGG), protein-protein interactions, expression levels and 
literature. Next, the Endeavour-based ranking (Ranking B) was combined with Ranking A to obtain a 
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functional prioritization of all genes that are mutated in the exome of the LNCaP PCa cell line. A list of 
the 50 genes that are ranked highest is available as supplementary data (Supplementary Table 3.1). 
Not surprisingly, nine of the top ten of genes in the final ranking are kinases that could have been 
activated or inactivated during oncogenesis. From the top 100 SNVs, 12 SNVs are located in genes 
that have been found to be mutated in PCa genomes (Berger et al. 2011b, Kumar et al. 2011, Robbins 
et al. 2011, Taylor et al. 2010).  
 
3.4.5. Validation of SNVs 
To ensure that the observed mutations are no artifacts of the PCR-amplification that is part of the 
library preparation or of the Illumina sequencing, we independently performed a PCR-based 
amplification of the exonic regions containing the mutations followed by conventional Sanger 
sequencing (Figure 3.4). In 115 genes that are reported in literature to be involved in the 
development of PCa, we detected 14 SNVs and 12 SNPs. All these SNVs and SNPs were validated by 
capillary sequencing of genomic PCR products (Figure 3.5.A-B). Among these genes is the gene that 
encodes the androgen receptor (AR) harboring a known mutation in exon 8 (Veldscholte et al. 1990). 
This T877A mutation was detected in all 58 reads covering this base. The expression of all 14 SNV-
containing exons was verified by RNA sequencing (Figure 3.5.A). The presence of the 12 known SNPs 
(Figure 3.5.B) in this group of genes was also confirmed at the genomic DNA level. However, for 4 out 
of the 12 SNPs (CD44, FLT3, GSTP1 and RNASEL) no transcript could be generated.  
We also re-sequenced the regions around each of these SNVs and SNPs in other PCa cell lines 
(DU145, PC-3, CWR22Rv1 and VCaP). While SNPs could also be detected in these other PCa cell lines, 
as expected, this was not the case for our new SNVs (Figure 3.5.C-D).  
Aside from these SNVs and SNPs, we validated the presence of 16 other SNVs in the genomic DNA as 
well as in the transcriptome (Supplementary Figure 3.1). In total, for all 42 SNVs that were validated 
on the genomic LNCaP DNA, the presence of the variant was confirmed with Sanger sequencing. 
While this is only a small sample of the SNVs, it illustrates the low false positive rate which is a 
consequence of the stringent filtering method we applied.  
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Figure 3.4. Validation of SNVs and SNPs with PCR and Sanger sequencing. Sanger sequence traces 
from non-synonymous mutations in the LNCaP exome. The mutation in the androgen receptor is an 
example of a homozygous SNV, while the ERBB2 gene contains a heterozygous SNV. The mutated 
position is arrowed.  
 
3.4.6. Genomic stability of the LNCaP cell line 
LNCaP cells are known to show inter-laboratory variability, even when they are all derived from the 
same tumor sample and most likely even from a single cancer cell. However, it is unclear whether 
this is due to phenotypic or genotypic adaptations. In addition, the presence of two alternative bases 
at any specific position could be due to heterozygosity or heterogeneity of the culture. Therefore, the 
presence of SNVs and SNPs was verified in LNCaPs from different laboratories (LNCaP (UK) and LNCaP 
(NL)), in a monoclonal cell line derived from LNCaP cells (LNCaP TR2) and in a cell line derived from 
LNCaP cells after xenografting in nude mice (C4-2B cells). Most SNVs and SNPs were found in all cell 
lines (Figure 3.5.A-B). This demonstrates that the LNCaP cells are heterozygous for these SNVs and 
SNPs. Moreover, the fact that the SNVs in the E-cadherin, CDK4, Notch1 and PlexinB1 genes are 
present in some sublines, but absent in LNCaP TR2 and LNCaP (UK) might indicate some form of 
genetic instability. 
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Figure 3.5. Validation of SNVs and SNPs in the LNCaP exome. Validation was performed using PCR on 
both genomic DNA and copy-DNA, followed by conventional Sanger sequencing. The first and second 
column of each table represents the name of the gene and the amino acid substitution respectively. 
A and B, validation of SNVs and SNPs respectively on genomic DNA and copy-DNA from the LNCaP 
cells cultured in our laboratory, from LNCaP cells from other laboratories (LNCaP (UK) and LNCaP 
(NL)), from a monoclonal derivative of LNCaP cells (LNCaP TR2) and from a cell line derived from 
LNCaP cells after xenografting in nude mice (C4-2B). C and D, validation of SNVs and SNPs 
respectively on genomic DNA from other PCa cell lines (VCaP, DU145, PC-3 and CWR22Rv1). A + sign 
denotes that the SNV or SNP was detected, a – sign that the SNV or SNP was not detected and / 
means that no PCR-product could be amplified.  
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3.5. DISCUSSION 
3.5.1. Exome analysis 
The re-sequencing of the exome of LNCaP cells generated a comprehensive catalogue of 1802 SNVs, 
67 insertions and 151 deletions specific for this PCa cell line. As there is no normal tissue from the 
corresponding patient available, it is possible that some of the novel variants we found are germ line 
SNPs not yet reported in the dbSNP database. However, most of them will more likely be mutations 
that originated either during carcinogenesis or during the culturing of these cells. Our SNV catalogue 
includes the majority of mutations present in LNCaP cells since it is based on 78% of exonic 
nucleotides that were covered 12x or more. Extrapolation reveals that, at least in theory, the 
complete LNCaP exome would contain over 2300 SNVs. With our validation study using PCR-
amplification and capillary sequencing, we confirmed the presence of 42 SNVs in the original LNCaP 
culture, illustrating the quality resulting from our stringent filtering criteria. On the other hand, some 
SNVs will have escaped detection because we maintained a severe filtering of the sequencing data. A 
less stringent filtering would lead to the detection of more SNVs, but this would be at the expense of 
specificity, since false positive SNV predictions would increase. A ten-fold read depth was e.g. applied 
by Chang et al., but the rate of false positive SNVs was not reported (Chang et al. 2011).  
At first, we looked for SNVs and SNPs in 115 cancer-related genes that had been connected with PCa 
in literature before. From these, we found 25 genes to contain a SNV and/or SNP in the LNCaP exome 
(Figure 3.5). For twenty-two of the 25 genes, other mutations had already been described in PCa 
biopsies (Assinder et al. 2009, Dong 2006, Grindedal et al. 2009, Hughes et al. 2005, Mimeault et al. 
2006, Wong et al. 2007). Furthermore, 16 of these genes were found to be mutated in a limited 
number of PCa samples analyzed with next-generation sequencing technologies (Berger et al. 2011b, 
Kumar et al. 2011, Robbins et al. 2011, Taylor et al. 2010).  
For most tested SNVs, expression was demonstrated by reverse transcriptase-PCR of LNCaP polyA-
RNA. Even when two alternative bases were called in the high-throughput sequencing, both could be 
detected in the RNA, and when a homozygous SNV or SNP was validated, only this base was detected 
in the transcriptome. Thus, for all SNVs both the wild type and the mutated genes are expressed in 
the LNCaP cells. However, for four SNPs, we could not detect transcripts, and this is in accordance 
with microarray data available for LNCaP cells indicating that these genes are not expressed in LNCaP 
cells (Oudes et al. 2005). However, we cannot conclude whether the repression of these variant 
alleles happened before, during or even after the oncogenic process. Not surprisingly, none of the 
SNVs and only part of the SNPs that were tested (Figure 3.5) are present in other PCa cell lines (VCaP, 
DU145, PC-3 and CWR22Rv1).  
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The number of SNVs identified in the LNCaP cell line is higher than what we would have predicted, 
certainly when compared to the number of SNVs found in the genome or exome of other cancer cell 
lines, even when a less stringent filtering was applied (Chang et al. 2011, Clark et al. 2010). For 
example, whole genome sequencing of the U87MG glioma cell line identified 1036 non-synonymous 
coding SNVs with less strict filtering criteria, while whole exome sequencing of the PC-3 PCa cell line 
identified only 200 high-confidence non-synonymous coding SNVs (Chang et al. 2011, Clark et al. 
2010).  
 
3.5.2. Defining prostate cancer driver mutations 
Prostate adenocarcinoma is the most frequently diagnosed malignancy in men and it is the second 
leading cause of cancer deaths among men in Western countries (Parkin et al. 2005). Its biological 
heterogeneity is a major cause of the overtreatment and undertreatment of 30 to 50% of PCa 
patients (Cooperberg et al. 2005). The limited genomic data available from PCa biopsies indicate that 
PCa seems to have a low frequency of mutations (Kan et al. 2010, Taylor et al. 2010). The most 
frequent PCa-related mutations are gene rearrangements (Tomlins et al. 2005), but these were not 
tested in this study.  
Identifying genomic changes in PCa would be a valuable diagnostic tool (Berger et al. 2011b, Robbins 
et al. 2011, Taylor et al. 2010), but as for all exome and genome sequencing studies, distinguishing 
which mutations matter is challenging. Indeed, cancer somatic mutations can be subdivided in two 
main biological classes: driver mutations, which confer selective clonal growth advantages, are 
causally implicated in oncogenesis, while passenger mutations have not contributed to the 
development of the cancer and hence have not been subjected to direct selection. It should be noted 
here that when looking at variants in cell lines, these could have originated even after the 
carcinogenesis during the process of in vitro culturing of the cells.  
The ratio of non-synonymous to synonymous mutations is a first reliable indicator for some form of 
selective pressure, as synonymous alterations are unlikely to exert a selective growth advantage 
(Bardelli et al. 2003). Applied to our data, we found a ratio of 2.1:1 which is not higher than the ratio 
of 2:1 predicted for non-selected passenger mutations. This information, combined with the fact that 
only 7% of all SNVs are predicted to be deleterious according to all three in silico programs (SIFT, 
PolyPhen2 and MutationAssessor), suggests that the majority of the SNVs we identified are 
functionally neutral and most likely ‘passenger’ mutations. It should be noted however that the 
classical discrete, step-wise model of tumor suppression is being replaced by the concept of a 
dosage-dependency of tumor suppressor gene function influenced by smaller changes in many gene 
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products (Berger et al. 2011a). In this concept, many of the variants that would be called passenger 
mutations based on the Endeavour protocol could at some point have contributed to the oncogenic 
process. 
In the present study, we focused on non-synonymous coding variants. However, it has been 
suggested that synonymous variants or variants in untranslated regions could still have a powerful 
impact by altering the level of gene expression through alteration of miRNA binding (Berger et al. 
2011a).  
 
3.5.3. In silico search for driver mutations 
Our exome re-sequencing data set was used to devise a prioritization protocol which returns a list of 
SNVs in genes that might have an impact on protein structure or function. For Ranking A, we choose 
to combine three separate prediction software programs, because each program has its own 
assumptions and its own advantages and disadvantages. Ranking B was created using the Endeavour 
software and includes different gene information sources. Furthermore, it allowed the combination 
of ranking A and B. The observation that nine of the top ten of genes in the final ranking are kinases 
has implications for the use of LNCaP cells as a model for PCa, for example in preclinical testing of 
kinase inhibitors or in the study of gene knock down by siRNA. A gene ontology analysis of the top 
hundred of highest ranked genes resulted in the following most perturbed cell functions: cell death, 
cellular growth and proliferation, cellular development, cell cycle and cellular movement.  
 
3.5.4. Interference with androgen responsiveness 
Initial androgen responsiveness and later acquired castration resistance are important topics in PCa 
research. First of all, we confirmed that the LNCaP cell line is homozygous for the 877 mutation in the 
AR gene. In addition, some of our highly ranked proteins (CDK9 and HoxB13) are known to be 
involved in the androgen response (Gordon et al. 2010, Norris et al. 2009). Moreover, protein kinase 
C beta, recently described as an important player in the androgen-induced histone code (Metzger et 
al. 2010), is heterozygous for K489 to N in LNCaP cells. Taylor et al. reported a higher frequency of 
mutations in the AR pathway (including several known AR coactivators and corepressors). We 
detected 21 mutations in possible AR coregulators, but these need further analysis to determine 
their impact on the androgen response. Indeed, whether these LNCaP mutations or combinations 
thereof have contributed to the carcinogenesis, the metastasis or the evolution into castration-
resistance as commonly seen for PCa remains to be determined. 
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 3.5.5. Are LNCaP cells genetically unstable, heterogeneous and/or heterozygous? 
LNCaP cells are homozygous for only 98 of the 1802 SNVs, which is in agreement with the reported 
polyploidy of LNCaP cells and a limited loss of heterozygosity (Horoszewicz et al. 1983). For most 
SNVs (94.6%), we detected two alternative nucleotides. This could be the consequence of either 
heterozygosity or heterogeneity of the LNCaP cells. However, most SNVs and SNPs were also present 
in genomic DNA of LNCaP cells from another source (LNCaP UK), as well as from a monoclonal 
derivative (LNCaP TR2) and in the syngeneic C4-2B cell line (Figure 3.5). Since heterogeneity would 
most likely have been lost during the monoclonal derivation, the presence of two alternatives at 
most SNVs can only be explained by the fact that the LNCaP cells are heterozygous rather than 
heterogeneous for these SNVs and SNPs.  
Surprisingly, four out of 14 SNVs were absent in the LNCaP (UK) cells as well as in the derived LNCaP 
TR2 clone. The presence of three of these four SNVs (E-cadherin, CDK4, and Notch1) was confirmed 
in LNCaP cells from a third source (LNCaP NL) as well as in the C4-2B cell line. The fact that some 
LNCaP cell lines have lost heterozygosity of some SNVs indicates that the LNCaP genome is unstable 
to some extent. Interestingly, the SNV in the PlexinB1 gene was only found in our LNCaP cells and not 
in any of the other cell lines we tested. This mutation was already reported in LNCaP cells (Wong et 
al. 2007) and its presence was proposed to be linked with an adaptation of the cells to the growth 
conditions on plastic surfaces, as the mutant protein had significantly increased adhesion capacities.  
 
 
3.6. CONCLUSIONS 
In conclusion, we present a nearly complete exome sequence of the LNCaP PCa cell line. We report 
1802 non-synonymous single nucleotide variants, 67 small insertions and 151 small deletions. The 
presence of SNVs detected in our LNCaP cells in other LNCaP (derivative) cell lines indicates that they 
are mainly heterozygous, but to some degree also heterogeneous or genomically unstable. Although 
this is accepted for most cancer cell lines, this remained to be documented for LNCaP cells. The SNVs, 
the SNPs and the heterogeneity between cultures should be taken into account when performing 
experiments in LNCaP cells for basic as well as preclinical studies.  
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3.8. SUPPLEMENTARY INFORMATION 
 
Supplementary table 3.1. Top 50 of genes ranked highly with in silico prioritization protocol. This 
table lists 50 genes that were ranked highest using our in silico prioritization protocol. 
1 RIPK2 
 
Receptor-interacting serine/threonine-protein kinase 2 
2 CHEK2 
 
Serine/threonine-protein kinase Chk2 
  3 PRKCB1 
 
Protein kinase C beta type 
   4 RET 
 
Proto-oncogene tyrosine-protein kinase receptor ret precursor 
5 CSNK1G2 
 
Casein kinase I isoform gamma-2 
  6 MELK 
 
Maternal embryonic leucine zipper kinase 
 7 ZAP70 
 
Tyrosine-protein kinase ZAP-70  
  8 CDK9 
 
Cell division protein kinase 9 (Cyclin-dependent kinase 9) 
9 KLK3 
 
Prostate-specific antigen precursor (Kallikrein- 3)  
 10 GAB1 
 
GRB2-associated-binding protein 1  
  11 FLT4 
 
Vascular endothelial growth factor receptor 3 precursor 
12 COL5A1 
 
Collagen alpha-1(V) chain precursor 
  13 TERT 
 
Telomerase reverse transcriptase  
  14 PIK3R4 
 
Phosphoinositide 3-kinase regulatory subunit 4 
 15 HSD17B4 
 
17-beta-hydroxysteroid dehydrogenase 4 
 16 EHMT1 
 
Euchromatic Histone-lysine N-methyltransferase 1 
 17 PTK7 
 
Tyrosine-protein kinase-like 7 precursor 
  18 CAMK2G 
 
Calcium/calmodulin-dependent protein kinase type II gamma chain  
19 SMO 
 
Smoothened homolog precursor 
  20 DAB2 
 
Disabled homolog 2  
   21 CAPZA1 
 
F-actin capping protein subunit alpha-1 
  22 ATP1A1 
 
Sodium/potassium-transporting ATPase alpha-1 chain precursor 
23 CAMK2B 
 
Calcium/calmodulin-dependent protein kinase type II beta chain 
24 TLN1 
 
Talin-1 
     25 MYC 
 
Myc proto-oncogene protein 
   26 CBLB 
 
E3 ubiquitin-protein ligase CBL-B  
  27 SOCS7 
 
Suppressor of cytokine signaling 7  
  28 RASGRP2 
 
RAS guanyl releasing protein 2 isoform 2 
  29 MYLK 
 
Myosin light chain kinase, smooth muscle  
 30 HNRPH3 
 
Heterogeneous nuclear ribonucleoprotein H3  
 31 VAV1 
 
Proto-oncogene vav 
   32 GNA11 
 
Guanine nucleotide-binding protein subunit alpha-11  
33 GNAI3 
 
Guanine nucleotide-binding protein G(k) subunit alpha-3 
34 UCP2 
 
Mitochondrial uncoupling protein 2 
  35 RBL2 
 
Retinoblastoma-like protein 2 
   36 NSMAF 
 
Protein FAN  (Factor associated with neutral sphingomyelinase activation) 
37 LTA4H 
 
Leukotriene A-4 hydrolase  
   38 MYH14 
 
Myosin heavy chain 14 
   39 DIABLO 
 
Diablo homolog, mitochondrial precursor  
 40 ABI1 
 
Abl interactor 1 (Abelson interactor 1) 
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41 ELAVL1 
 
ELAV-like protein 1 
    42 G3BP1 
 
Ras GTPase-activating protein-binding protein 1 
 43 HSD17B10 3-hydroxyacyl-CoA dehydrogenase type-2  
 44 TCEA2 
 
Transcription elongation factor A protein 2  
 45 FGF5 
 
Fibroblast growth factor 5 precursor  
  46 AGA 
 
N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase precursor  
47 EPHB4 
 
Ephrin type-B receptor 4 precursor 
  48 TSC22D3 
 
TSC22 domain family protein 3  
  49 RNF34 
 
E3 ubiquitin-protein ligase RNF34 (RING finger protein 34)  
50 HNRPL 
 
Heterogeneous nuclear ribonucleoprotein L 
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Supplementary figure 3.1. Validation of additional SNVs in the LNCaP exome. The first and second 
column of each table represents the name of the gene and the amino acid substitution respectively. 
The validation was performed using PCR on both genomic DNA (third column) and copy-DNA (fourth 
column), followed by conventional Sanger sequencing. A + sign denotes that the SNV or SNP was 
detected, a – sign that the SNV or SNP was not detected and / means that no PCR-product could be 
amplified.  
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4.1. ABSTRACT 
The LNCaP and C4-2B cell lines form an excellent preclinical model to study the development of 
metastatic castration-resistant prostate cancer, since C4-2B cells were derived from a bone 
metastasis that grew in nude mice after inoculation with the LNCaP-derived, castration-resistant C4-2 
cells. Exome sequencing detected 2188 and 3840 mutations in LNCaP and C4-2B cells respectively, of 
which 1784 were found in both cell lines. Surprisingly, the parental LNCaP cells have over 400 
mutations that were not found in the C4-2B genome. More than half of the mutations found in the 
exomes were confirmed by analyzing the RNA-seq data and we observed that the expressed genes 
are more prone to mutations than non-expressed genes. The transcriptomes also revealed that 457 
genes show increased expression and 246 genes show decreased expression in C4-2B compared to 
LNCaP cells.  
By combining the list of C4-2B-specific mutations with the list of differentially expressed genes, we 
detected important changes in the focal adhesion and ECM-receptor interaction pathways. 
Integration of these pathways converges on the myosin light chain kinase gene (MLCK) which might 
contribute to the metastatic potential of C4-2B cells.  
In conclusion, we provide extensive databases for mutated genes and differentially expressed genes 
in the LNCaP and C4-2B prostate cancer cell lines. These can be useful for other researchers using 
these cell models.  
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4.2. INTRODUCTION 
Prostate cancer (PCa) is the most frequently diagnosed cancer and third leading cause of death 
amongst men in Europe (Ferlay et al. 2013). Despite its prevalence, a majority of men is diagnosed 
with localized, low-risk PCa and would never die because of their cancer when left untreated (Lu-Yao 
et al. 2009). However, patients with high-risk and especially metastatic disease have a much higher 
risk of dying from PCa with reported PCa-specific mortality rates up to 28.8% for high-risk disease 
and 66.1% for metastatic disease at 10-years follow-up (Rider et al. 2013). Recent epidemiological 
data have shown that almost 10% of all PCa patients are metastatic at the time of diagnosis, 
underlining the clinical importance of developing a better insight in the underlying mechanisms of 
metastatic PCa (Siegel et al. 2012). The genomic and transcriptomic changes that accompany the 
transformation of localized disease to metastatic castration-resistant PCa are being discovered, but 
are obstructed by the difficulties to obtain biopsies from the different stages of the disease (Haffner 
et al. 2013, Spans et al. 2013). 
As an alternative, cell lines can be used as models to study the transition to metastatic castration-
resistant PCa (Sampson et al. 2013). One of the best studied PCa cell lines undoubtedly is the LNCaP 
cell line. This cell line was derived from a needle biopsy taken from the left supraclavicular lymph 
node of a 50-year old Caucasian male (Horoszewicz et al. 1980). This patient suffered from a rapidly 
progressing PCa with minimal and brief response to hormonal therapy and no response to 
chemotherapy. Subsequently, the C4-2 subline was derived from a tumor that developed in castrated 
nude mice injected with LNCaP cells. Finally, the C4-2B cell line was derived from a bone metastasis 
after orthotopic transplantation of C4-2 cells in nude mice (Ianculescu et al. 2012, Thalmann et al. 
1994). In other words, C4-2B is a metastatic derivative of the LNCaP cells. The LNCaP and C4-2B 
progression model therefore mimics the disease advancing from poorly tumorigenic, androgen-
sensitive and non-metastatic in LNCaP, to metastatic and androgen-insensitive (or castration-
resistant) in C4-2B.  
For these two cell lines, changes in karyotype and genomic copy numbers, some point mutations, 
insertions and deletions have been described, but the comparison of the exome sequences has not 
been reported yet (Pan et al. 1999, Thalmann et al. 1994). The first goal of this study was therefore 
to obtain comprehensive exome data for LNCaP and C4-2B cells. Of course, a comparison of these 
mutational landscapes only makes sense in the presence of information on the activity of the 
affected genes. The latter was obtained from transcriptome analyses.  
A first step to catalogue point mutations, insertions and deletions in the LNCaP cells was reported in 
Spans et al. (Spans et al. 2012). Here, we report on a comparative whole exome and transcriptome 
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sequencing study of both LNCaP and C4-2B cell lines. To our knowledge, this is the first direct and 
thorough comparison of this kind. Moreover, these databases can be very informative for preclinical 
studies for which both LNCaP and C4-2B cells are being used. They can also be used to generate 
hypotheses on the metastatic process, as exemplified for the MLCK pathway.  
 
 
4.3. MATERIALS AND METHODS 
4.3.1. DNA isolation 
The LNCaP cell line was obtained from the American Type Culture Collection, while the  
C4-2B cells were a kind gift from Dr. M. Stallcup (Norris Comprehensive Cancer Center, University of 
Southern California, USA) (Thalmann et al. 1994). Both cell lines were grown in Roswell Park 
Memorial Institute medium (RPMI, Gibco, Invitrogen), containing 2 g/L glucose supplemented with 
10% heat-inactivated fetal calf serum (FCS). The passage number of the LNCaP and C4-2B cells was 48 
and 42 respectively. High-molecular weight DNA was extracted from cultured cells using the 
GenElute Mammalian Genomic DNA Miniprep kit (Sigma-Aldrich). After purification using ethanol 
precipitation with ammonium acetate, the concentration was quantified using a Nanodrop ND-1000 
spectrophotometer (Thermo Fisher Scientific) and BioAnalyzer (Agilent).  
 
4.3.2. Whole exome sequencing  
Whole exome capture of the LNCaP cells was performed using the SureSelect Human All Exon System 
(Agilent) according to the manufacturer’s instructions. Paired-end, 100 bp long sequencing reads 
were generated using the GAIIx sequencer (Illumina). The exome capture of the C4-2B cells was 
performed using the SeqCap EZ Exome version 2 kit (Roche Nimblegen) and paired-end 100 bp long 
reads were generated using the HiSeq2000 (Illumina).  
Quality control was performed using FastQC software (version 0.10.1) 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/) and Picard (version 1.22) 
(http://picard.sourceforge.net/). Sequencing reads were aligned to the human reference genome 
(hg19, NCBI Build 37) using BWA, where reads were trimmed when the quality was below 15 (version 
0.5.9) (Li et al. 2009a). Alignment files were processed further with Genome Analysis Toolkit (GATK) 
before variant calling and included duplicate removal, local realignment around known indels and 
base quality recalibration (version 1.0.5777) (McKenna et al. 2010). The samples were loaded 
individually to the GATK UnifiedGenotyper software. Point mutations and expression data were 
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plotted using the Circos software (version 0.52) (Krzywinski et al. 2009). Comparison of point 
mutations was performed using Venny (http://bioinfogp.cnb.csic.es/tools/venny/index.html).  
 
4.3.3. RNA isolation  
LNCaP and C4-2B cells, with passage numbers of 30 and 43 respectively, were plated in 6-well plates 
(1.75 million cells/well) and treated overnight (18h) with 1 nM R1881 (Perkin Elmer). The cells were 
collected and washed with PBS. The cell pellet was used to extract total RNA using the RNeasy Mini 
Kit from Qiagen. The quality and purity of the RNA was inspected on a Nanodrop ND-1000 
Spectrophotometer. The integrity of the RNA was verified on the BioAnalyzer at the Genomics Core 
of UZ Leuven.  
 
4.3.4. RNA sequencing 
After selection of polyA+ RNA, the RNA was converted into cDNA libraries using the TruSeq RNA 
Sample Preparation kit (Illumina). After sequencing paired-end short reads of 100 bp with the 
HiSeq2000 (Illumina), normalized gene counts (Fragments Per Kilobase per Million of mapped reads, 
FPKM) were calculated via the Tuxedo pipeline (Tophat – Cufflinks – CummeRbund) (Trapnell et al. 
2012). In short, the RNA-seq data were aligned to the reference genome using TopHat (version 2.0.6) 
that utilizes Bowtie as the algorithmic core. The Cufflinks package (version 2.0.2) assembled the 
transcripts and detected differentially expressed genes and transcripts. CummeRbund (version 2.0.0) 
was used to visualize the gene expression data. Variant calling using the RNA-seq data was 
performed with GATK (version 2.2), after alignment with Tophat (McKenna et al. 2010). RNA-seq for 
both cell lines was performed in triplicate, allowing the identification of differentially expressed 
genes. For variant calling, the triplicates were aggregated to obtain higher coverage. Pathway-
Express was used to determine, from a list of genes, whether in a specific pathway more genes are 
involved than would be expected by chance (Draghici et al. 2007).  
 
4.3.5. Quantitative RT-PCR 
cDNA was generated from RNA (1 µg) with Random Hexamer primers and RevertAid Reverse 
Transcriptase (Thermo Scientific). Quantitative Real Time PCR was performed using Platinum SYBR 
Green QPCR Supermix-UDG (Invitrogen). Results were normalized to the housekeeping gene beta-
actin and each sample was analyzed in triplicate. The sequence of the primers used are: beta-actin 
forward 5’-ACCCAAGGCCAACCG-3’ and reverse 5’-TGTACGTTGCTATCCAGGCTGT-3’, TMPRSS2 
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forward 5'-CCTGCATCAACCCCTCTAACTG-3' and reverse 5'-AGGCGAACACACCGATTCTC-3', IGF1 
forward 5'-TGGATGCTCTTCAGTTCGTG-3' and reverse 5'-TCATCCACGATGCCTGTCT-3', IGF1R forward 
5'-GTACAACTACCGCTGCTGGA-3' and reverse 5'-TGGCAGCACTCATTGTTCTC-3'.  
 
4.3.6. Accession numbers 
Binary sequence alignment/map (BAM) files from whole exome sequencing data as well as RNA-seq 
data were deposited in the database of the European Nucleotide Archive with accession number 
PRJEB4877 and are accessible via http://www.ebi.ac.uk/ena/data/view/PRJEB4877. The sample 
accession numbers are ERS363578 and ERS363580 for whole exome sequencing data of LNCaP and 
C4-2B respectively. For the RNA-sequencing, the sample accession numbers are ERS363579 and 
ERS363581 for LNCaP and C4-2B cells respectively.  
 
4.3.7. Confirmation of non-synonymous variants 
Variants of interest were confirmed by Sanger sequencing of amplified PCR products. Primers specific 
to the region containing the variant to be tested were designed using the NCBI Primer-Blast 
(http://ncbi.nlm.nih.gov/tools/primer-blast/) and obtained from Integrated DNA Technologies. 
Polymerase chain reactions were performed following standard protocols using Taq DNA polymerase 
(Thermo Scientific). Amplification of specific PCR fragments was confirmed by agarose gel 
electrophoresis. Sanger sequencing was performed at LGC Genomics. Sequence trace files were 
analyzed using Chromas Lite.  
 
 
4.4. RESULTS 
4.4.1. Detecting point mutations with whole exome sequencing 
We performed a whole-exome re-sequencing study for both LNCaP and C4-2B cells using 100 base 
pair, paired-end reads on the Illumina platform. This generated 49 and 80 million reads for LNCaP 
and C4-2B respectively (Supplementary table 4.1); for LNCaP cells, 74% of the exome was covered at 
least 20x, versus 88% for C4-2B cells. Sequencing characteristics and quality control data are similar 
for both datasets (Supplementary table 4.1 and Supplementary figure 4.1).  
The point mutations in the exomes were detected using the GATK pipeline to which additional 
filtering was applied: only mutations which had at least 12x coverage and a mutation frequency 
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above 30% were taken into account. Data were also filtered for absence of the base pair change in 
dbSNP130. Furthermore, strand bias was eliminated manually (Supplementary table 4.2). This 
resulted in lists of 2188 and 3840 non-synonymous point mutations in LNCaP and C4-2B cells, 
respectively (Supplementary table 4.3 and 4.4). Only 1784 mutations were common between both 
cell lines, clearly indicating the accumulation of more than 2000 additional mutations in the C4-2B 
genome. This large difference in mutation load cannot be explained by the slightly lower coverage of 
the LNCaP exome. Most likely, these additional C4-2B mutations have arisen during tumor 
progression and bone metastasis.  
 
4.4.2. Detecting point mutations in transcriptome sequencing 
Transcriptome sequencing was performed initially to determine differential gene expression. RNA 
was isolated from LNCaP and C4-2B cells that had been treated for 18 hours with the synthetic 
androgen methyltrienolone. We obtained 157 and 131 million 100 base pair, paired-end reads for 
LNCaP and C4-2B cells. In these reads, the percentage of ribosomal, intronic and intergenic bases was 
very low (1.6% in total), resulting in a high coverage of mRNA bases (Supplementary table 4.1). As a 
measure for the quality of the transcriptome data, the variation in coverage along each transcript is 
shown in Supplementary figure 4.2. This shows no 5’ or 3’ bias although there is a somewhat lower 
coverage near the ends of the transcripts.  
The workflow for the detection and subsequent filtering of point mutations was similar to that used 
for the exome sequencing described higher. We found 1505 and 1882 mutations in LNCaP and C4-2B 
cells respectively, of which 1054 were detected in both cell lines (Supplementary table 4.5); 451 were 
specific for LNCaP and 828 for C4-2B. 
 
4.4.3. Comparing exome with transcriptome sequencing data 
Comparing the read counts of variant alleles from genome and transcriptome sequencing data of all 
detected point mutations can be used as a measure of the sequencing quality. The majority of the 
mutations have a similar allele frequency in both DNA and RNA sequencing (Figure 4.1.A-B). Even the 
few homozygous mutations with allele frequency close to 1 in the exome data, have a similar allele 
frequency in the RNA sequencing data.  
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Figure 4.1. Comparison of variant allelic frequencies measured by whole exome and transcriptome 
sequencing. A-B. Comparison of the variant allelic frequency of mutations detected using whole 
exome and transcriptome sequencing. Black dots are mutations that have been found by both exome 
and transcriptome sequencing; red dots were only detected by exome sequencing and green dots 
only by RNA sequencing. For variant calling, a cut-off of 30% variant allelic frequency was applied. 
Next to the graph a figure shows the number of mutations from exome sequencing, transcriptome 
sequencing and the number found by both methods. Graphs are shown for LNCaP (A) and C4-2B cells 
(B) respectively. C. Overlap of all mutations observed by exome and transcriptome sequencing in 
LNCaP and C4-2B cells.  
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The combination of both the exome and transcriptome sequencing resulted in a total of 2244 
mutations common to both cell lines (Figure 4.1.C). Moreover, the number of LNCaP-specific 
mutations (546) is much lower than that of C4-2B-specific changes (2129), again indicating that 
mutations have accumulated during the progression to C4-2B. RNA-sequencing confirmed only 41 
and 35% of the exonic variants identified by whole exome sequencing of LNCaP and C4-2B. This 
number rose to 52% when we only took the expressed genes into account (FPKM > 1). Conversely, 60 
and 71% of the LNCaP and C4-2B variants identified by transcriptome sequencing respectively were 
confirmed by exome sequencing.  
 
4.4.4. Nucleotide substitutions 
The different types of transitions and transversions in the exomes and transcriptomes of LNCaP and 
C4-2B cell lines might give insight in the mutational processes that took place during the 
development of these cells. We observed that the predominant mutations (40-42%) in both cell lines 
were G-to-A and C-to-T transitions (Figure 4.2).  
 
 
Figure 4.2. Mutation spectrum of single nucleotide substitutions. Percentages of mutations in each of 
the six possible mutation classes are represented for the exome sequencing and transcriptome 
sequencing data of both LNCaP and C4-2B cells.  
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The most prevalent type of RNA editing in higher eukaryotes is the conversion of adenosine to 
inosine. As inosine is read as a guanine after sequencing, this editing type manifests itself in RNA-
sequencing as an A-to-G substitution (Dominissini et al. 2011). However, in our data sets, the number 
of A-to-G transitions in the exome and the transcriptome sequencing data is comparable arguing 
against an important role of RNA editing (Figure 4.2).  
 
4.4.5. Validation of point mutations 
In total, 80 mutations in the exome data from LNCaP (47) and C4-2B (33) were validated by manual 
Sanger re-sequencing (Figure 4.3). The genes that were chosen for validation were ranked high in a 
functional prioritization of all mutated genes in the C4-2B cell line (calculated as in (Spans et al. 
2012)). Nine of these mutations (in PIK3R1, TP53BP1, PRKCQ, CHEK2, RIPK2 and KLK3) were detected 
by DNA and RNA sequencing in both cell lines, and these were confirmed with Sanger sequencing on 
genomic and complementary DNA of LNCaP and C4-2B. When we tested seven of the C4-2B exome 
mutations (PIAS1 P216S and K380M, MKNK2 L229M and T244N, STAT5A I85N and MYO18A A1571T 
and Q646*), they were not detected by LNCaP exome sequencing, but their presence in the LNCaP 
genome was evident in the RNA sequencing data and also confirmed by Sanger sequencing on 
genomic and complementary DNA.  
We also detected and confirmed C4-2B specific mutations in CASP9, FLNB, POLR2A and STAT5A in 
genomic DNA and cDNA of C4-2B cells, but not in LNCaP cells. Finally, mutations in genes that are not 
expressed in LNCaP or C4-2B (KIT and GRAP) could only be confirmed on genomic DNA.  
In conclusion, the GATK UnifiedGenotyper for variant calling which we combined with our extensive 
filtering generated few false positives. Similar results were shown recently by Liu et al. by comparing 
GATK with SAMtools, Atlas 2 and glftools (Liu et al. 2013). Moreover, it should be noted that our 
validations indicated that the exome analyses did not uncover all mutations, but the variations that 
were discovered most likely are genuine mutations.  
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Figure 4.3. Validation of point mutations in the LNCaP and C4-2B cell lines. Validation was performed 
using PCR on both genomic DNA and copy-DNA, followed by conventional Sanger sequencing. The 
first and second column represents the name of the gene and the amino acid substitution 
respectively. The third, fourth, seventh and eighth column represent next-generation sequencing 
results for whole exome and transcriptome sequencing, which are then validated with Sanger 
sequencing in the fifth, sixth, ninth and tenth column. A + denotes that the mutation was detected, a 
– denotes that the mutation was not detected, while 0 means that no PCR-product could be 
amplified and / that this position was not covered with next-generation sequencing.  
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4.4.6. Differential gene expression between LNCaP and C4-2B cells 
We next wanted to search for differentially expressed genes between the two cell lines, since these 
might provide clues to the mechanisms behind the evolution of LNCaP cells into C4-2B cells. 
Differential expression was called by the Tuxedo algorithm based on RNA-seq data of triplicates for 
each cell line, with additional filtering of log2-fold change > 2 and q-value < 0.001. All replicates were 
very similar, as can be seen in Supplementary figure 4.3. Moreover, the squared coefficient of 
variation, which is a normalized measure of cross-replicate variability, is below 0.05 for expressed 
genes.  
Our analysis resulted in the identification of 703 differentially expressed genes (Supplementary table 
4.6), of which 457 genes are higher expressed in C4-2B and 246 are higher expressed in LNCaP cells 
(Supplementary figure 4.2). An overview of the location of differentially expressed genes across the 
genome can be found in Figure 4.4, together with the frequency of point mutations detected in both 
cell lines, in C4-2B cells only, or in LNCaP cells only. Quantitative RT-PCR on five differentially 
expressed genes confirmed the RNA-seq data (data not shown). 
Fu et al. already described some differentially expressed genes between LNCaP and C4-2B, but none 
of the genes they detected are differentially expressed in our data (Fu et al. 2002). We propose that 
culture conditions and differences between detection platforms most likely explain this discrepancy. 
On the other hand, there is considerable overlap of our datasets with those of other studies that 
compared LNCaP and C4-2 transcriptomes (Bisoffi et al. 2004, Liu et al. 2004, Oudes et al. 2005, 
Trojan et al. 2005, Xie et al. 2011). 
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Figure 4.4. Representation of the catalog of differentially expressed genes and mutations in LNCaP 
and C4-2B cells. Chromosome ideograms are shown around the outer ring and oriented pter-qter in a 
clockwise direction with centromeres indicated in red. The outer ring represents differentially 
expressed genes: 457 genes with higher expression in C4-2B (red dots) and 246 genes with higher 
expression in LNCaP (blue dots). Other tracks contain (from outside to inside): 2244 mutations in 
common between LNCaP and C4-2B cells, 2129 mutations specific for C4-2B cells and 546 mutations 
specific for LNCaP cells shown by density per 10 megabases.  
 
 
4.4.7. Pathway analysis of genomic and transcriptomic data sets 
LNCaP and C4-2B cells continue to be used in basic and preclinical research. We propose our 
databases of mutations and differentially expressed genes as important sources of inspiration for 
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further research projects. In addition, these databases can now be checked for specific mutations 
before one starts using these cells to study any specific PCa-related pathway.  
This paragraph gives an example of a hypothesis based on in silico analysis of our data. Pathway-
Express analysis of the C4-2B specific mutations combined with the 703 genes differentially 
expressed between LNCaP and C4-2B cells indicated that the most significant changes were found in 
the ECM-receptor interaction pathway and in focal adhesion. Both pathways converge in the 
upregulated expression of the myosin light chain kinase (MLCK) gene (Figure 4.5).   
 
Figure 4.5. Alterations in the pathway converging on overexpression of Myosin Light Chain Kinase in 
C4-2B cells. Alterations are defined as having an increased (green) or decreased (blue) expression in 
C4-2B compared to LNCaP or by somatic mutations in C4-2B cells only (bold black lines). 
Overexpression of myosin light chain kinase in C4-2B cells might distinguish them from LNCaP cells in 
cell migration and focal adhesion characteristics.  
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4.5. DISCUSSION  
4.5.1. A high mutation rate in LNCaP and C4-2B cells 
C4-2B cells are derived from a bone metastasis in nude mice inoculated with cells originating from 
the LNCaP-derived, castration-resistant xenografts called C4-2. They are considered a useful 
preclinical model for metastatic, castration-resistant and androgen receptor positive PCa. Here, we 
provide for the first time comparative maps of the point mutations detected in the LNCaP and C4-2B 
cells. In addition, although transcriptome analyses of LNCaP and C4-2 have been reported, to our 
knowledge, this is the first transcriptome analysis of C4-2B cells.  
C4-2B cells as well as LNCaP cells have a surprisingly high number of point mutations: 4373 and 2790 
mutations respectively. Like in primary PCa and castration-resistant PCa samples, the mutational 
spectrum is dominated by G-to-A and C-to-T transitions (Grasso et al. 2012, Lindberg et al. 2012, 
Weischenfeldt et al. 2013). It is known that mismatch repair defects cause transition mutations, 
particularly G-to-A and C-to-T substitutions (Lang et al. 2013). Hence, most mutations might be 
caused by the defective mismatch repair system in LNCaP cells, due to the homozygous deletion of 
the 3’ end of the MSH2 gene (Leach et al. 2000). Chen et al. already described a correlating high 
instability of satellite DNA in LNCaP cells (Chen et al. 2001).  
The number of point mutations in our cell lines is much higher than the average 16-33 mutations 
detected in whole exomes of PCa samples (Baca et al. 2013, Barbieri et al. 2012, Berger et al. 2011b, 
Weischenfeldt et al. 2013). These cell lines are therefore atypical, but might be considered a model 
for cases of PCa in which mismatch repair is defective as described for instance by Barbieri et al., 
where a single PCa tumor harbored a frameshift mutation of the MSH6 gene among 996 other 
mutations (Barbieri et al. 2012). Obviously, such higher mutation rates would explain the even higher 
number of mutations we found in C4-2B compared to LNCaP. Unfortunately, this will also obscure 
the driver mutations that may have conferred a survival advantage during the metastatic process.  
 
4.5.2. Link between mutation rates and expression 
For both the LNCaP and C4-2B cell line, we see that highly expressed genes more frequently contain 
point mutations than non-transcribed genes (p < 0.0001, Chi Square test, for the highest versus 
lowest expressed tertile). This contradicts the general link between heterochromatin organization 
and higher regional mutation rates in human cancer cells (Schuster-Bockler et al. 2012). Possibly, in 
these cell lines, the open chromatin and linked transcription induces more mismatches which 
normally are efficiently corrected, but not in case of a deficient mismatch repair. 
Exome and transcriptome analyses of LNCaP and C4-2B cells 
 
63 
 
4.5.3. Comparison of LNCaP and C4-2B mutations 
We detected 1784 shared mutations in the exomes of LNCaP and C4-2B, and 2056 C4-2B-specific 
changes, which makes sense since the C4-2B cells are derived from the LNCaP cells. However, we also 
detected 404 LNCaP-specific changes, many of which were confirmed by our transcriptome 
sequences. Obviously, the LNCaP cells we analyzed have deviated from the LNCaP cells that were 
used originally to develop the C4-2B cells (Thalmann et al. 1994). Indeed, we have shown earlier that 
even LNCaP cells from different labs are genetically different and while our cells were obtained from 
ATCC (passage 48), the C4-2B were most likely derived from a much earlier passage of LNCaP cells in 
1994 (Spans et al. 2012, Thalmann et al. 1994).   
 
4.5.4. Suggestion of a role of MLCK in the metastatic process 
Our data can clearly lead to the hypothesis on the metastatic process that took place during the 
conversion of LNCaP to C4-2B cells. This is exemplified by the convergence of a number of affected 
pathways to an upregulation of MLCK. Indeed, there are several published links between MLCK and 
the metastatic process. Discriminant analysis of microarrays identified the MLCK gene as the most 
informative gene for the PCa genesis process (Fujita et al. 2008), and inhibition of MLCK in rat PCa 
cells results in reduction of invasiveness, which was principally due to impaired cellular motility 
(Tohtong et al. 2003). Inhibiting MLCK in fibrosarcoma, pancreatic cancer and breast cancer cells also 
results in decreased adhesion, migration and invasion and increased apoptosis (Cui et al. 2010, Fazal 
et al. 2005, Kaneko et al. 2002, Niggli et al. 2006). Conversely, activating MLCK leads to an increase in 
invasion in breast cancer cells and an increased metastatic potential in non-small cell lung cancer 
(Khuon et al. 2010, Minamiya et al. 2005). The differential expression of the MLCK gene in the two 
cell lines investigated here might therefore correlate with the higher metastatic capacity of the C4-2B 
cells. 
 
In conclusion, our data clearly show that there are major differences in the number and distribution 
of mutations and gene expression between LNCaP and C4-2B cells. Since these cell lines are 
universally used to study the progression from non-metastatic to metastatic PCa, these data are 
crucial for researchers to correctly interpret their results when using these cell lines. Moreover, our 
databases will be very helpful in developing new investigational ideas. 
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4.7. SUPPLEMENTARY INFORMATION 
 
 
Supplementary table 4.1. Sequencing characteristics 
Supplementary table 4.2. Filters used to identify point mutations in the exomes of LNCaP and C4-2B 
cells 
Supplementary table 4.3. List of 2188 non-synonymous point mutations detected in LNCaP cells 
The table is not included in this thesis due to space constraints and can be obtained through the 
published article.  
Supplementary table 4.4. List of 3840 non-synonymous point mutations detected in C4-2B cells 
The table is not included in this thesis due to space constraints and can be obtained through the 
published article.  
Supplementary table 4.5. Filters used to identify point mutations in the transcriptomes of LNCaP and 
C4-2B cells 
Supplementary table 4.6. List of 703 genes differentially expressed between LNCaP and C4-2B cells 
The table is not included in this thesis due to space constraints and can be obtained through the 
published article.  
 
 
Supplementary figure 4.1. FastQC quality control results of the per base qualities 
Supplementary figure 4.2. Normalized coverage by position 
Supplementary figure 4.3. Heatmap of 703 differentially expressed genes 
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Supplementary table 4.1. Sequencing characteristics       
 
Whole exome sequencing RNA sequencing 
  LNCaP C4-2B LNCaP C4-2B 
Total reads 49790757 80299454 157583847 131925448 
Aligned HQ reads 34791304 73388716 155837048 130536483 
Aligned bases 3454982953 7455182568 15915376614 13323971443 
HQ aligned Q20 bases 3085390366 6710948381 15016055477 12559510784 
Percentage aligned reads that passed  filter 76,70% 98,00% 100% 100% 
Mean read length 101 101 101 101 
     Zero coverage targets 6,33% 1,52% 
  Percentage target bases 10x 79,04% 93,18% 
  Percentage target bases 20x 74,56% 88,84% 
  
     Percentage ribosomal bases 
  
0,0001% 0,0001% 
Percentage UTR bases 
  
32,4079% 30,8155% 
Percentage intronic bases 
  
0,7241% 0,7388% 
Percentage intergenic bases 
  
0,9193% 0,9151% 
Percentage mRNA bases     98,3566% 98,3459% 
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Supplementary table 4.2. Filters used to identify point mutations in the  
exomes of LNCaP and C4-2B cells     
Number of SNVs LNCaP C4-2B 
Predicted 514 295 380 691 
Not 'lowqual' according to GATK 143 004 157 708 
Not present in dbSNP130 23 896 38 648 
With coverage ≥ 12x 10 165 29 450 
With mutation allelic frequency ≥ 30% 7 898 18 718 
Nonsense or missense 2 302 4 562 
Without strand bias 2 188 3 840 
In common 1 784 
Mutation allelic frequency denotes the number of reads containing the  
mutation divided by the total number of reads.  
  
 
 
 
 
Supplementary table 4.5. Filters used to identify point mutations in the  
transcriptomes of LNCaP and C4-2B cells     
Number of SNVs LNCaP C4-2B 
Predicted 27 748 32 594 
Not 'lowqual' according to GATK 15 250 18 655 
With coverage ≥ 12x 12 532 15 807 
With mutation allelic frequency ≥ 30% 6 872 7 669 
Not present in dbSNP130 6 802 7 606 
Nonsense or missense 1 551 1 932 
Without strand bias 1 606 1 881 
In common 1 054 
Mutation allelic frequency denotes the number of reads containing the 
mutation divided by the total number of reads.  
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Supplementary figure 4.1. FastQC quality control results of the per base qualities. Output results of 
the FastQC quality control software (version 0.10.1) are shown here for exome and transcriptome 
sequencing of LNCaP and C4-2B cells.  
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Supplementary figure 4.2. Normalized coverage by position. The average relative coverage is shown 
at each relative position along the transcript’s length. LNCaP is depicted in green, while C4-2B is 
depicted in red. The x-axis represents the gene length normalized to 100%, where 0 is the 5’ end of 
each transcript and 100 is the 3’ end.  
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Supplementary figure 4.3. Heatmap of 703 differentially expressed genes. The heatmap shows the 
three replicates of each cell line, which are very similar. All differentially expressed genes were 
detected using the Tuxedo algorithm, with q < 0.001 and log2-fold change > 2 as cut-offs. It is clear 
that the majority of genes is upregulated in C4-2B compared to LNCaP, while a smaller group of 
genes is downregulated in C4-2B.  
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CHAPTER 5: 
GENOMIC ANALYSIS OF HIGH-RISK PROSTATE CANCER REVEALS LOSS-OF-FUNCTION 
MUTATIONS IN RFC1 AND TET1  
 
The work presented in this chapter has been conducted by the PhD candidate, unless otherwise 
stated in the figure legends.  
 
5.1. ABSTRACT 
Prostate cancer is the second most frequently diagnosed cancer in males worldwide. A wide range of 
genomic alterations, including point mutations, copy number changes and rearrangements, can lead 
to the development of cancer. Here, we report on the exome sequencing and copy number 
aberrations of 27 high-risk primary prostate tumors and their normal tissue pairs. These prostate 
cancer samples were collected within the PEARL consortium (ProstatE cAncer Research team 
Leuven). In addition to the amplifications and deletions that were described before, we identified a 
novel amplification on 7p22.3. Exome sequencing revealed one hypermutated sample containing 451 
mutations, compared to an average of 19 mutations in the other samples, indicating that DNA repair 
is compromised. This hypermutated tumor harbored a mutation in the DNA-repair gene Replication 
Factor C (RFC1). The mutation is predicted to affect the interaction with PCNA and hence the 
recruitment of DNA polymerases to PCNA. In a second tumor, we detected a novel point mutation in 
the TET1 gene (Ten-Eleven Translocation 1). This methylcytosine dioxygenase converts 5-
methylcytosine to 5-hydroxymethylcytosine, which leads to demethylation of cytosine and might 
lead to gene expression changes or altered chromatin organization. MeDIP-Seq and hMeDIP-Seq 
experiments performed on the tumor sample containing the A1908S TET1 mutation demonstrated 
an overall hypo-hydroxymethylation and hypermethylation at specific genomic loci, when compared 
to two other tumor samples without mutation in TET1. This effect was corroborated by the in vitro 
effect of the mutation on the dioxygenase activity as assessed by dot blot assays. We further showed 
that there is an overlap between the groups of androgen-regulated genes and the TET1-regulated 
genes. Moreover, TET1 is a coactivator of the androgen receptor. From the above data, we conclude 
that the A1908S TET1 mutation as detected in a high-risk primary prostate cancer leads to partial loss 
of TET1 tumor suppressor activity.  
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5.2. INTRODUCTION 
Prostate cancer (PCa) is the most frequently diagnosed cancer amongst males in Belgium and in 
Europe (Ferlay et al. 2013, Hsu et al. 2012). In Belgium, 9036 new cases were diagnosed in 2011 
(www.kankerregister.org). There is a large, uncharacterized clinical heterogeneity between patients 
diagnosed with PCa, with some patients dying of metastatic disease within two or three years after 
diagnosis, while other patients can live for 20 years with organ-confined disease. This clinical 
heterogeneity is most likely a reflection of the underlying genetic diversity. To obtain a better 
understanding of these genomic changes, we need large scale PCa genome characterization projects. 
Due to the relatively small tumor size and the admixture of stroma and non-tumoral tissue, such 
projects are not as easy for PCa as they are for other cancers. Nevertheless, the contribution of 
somatic base pair mutations to the oncogenic process has recently been studied in large cohorts, for 
both primary and metastatic PCa (Barbieri et al. 2012, Grasso et al. 2012). In addition to well-known 
dysregulated genes involved in chromatin modification, cell-cycle regulation and androgen signaling, 
they identified novel recurrently mutated genes such as SPOP in primary PCa and FOXA1 in 
castration-resistant PCa (CRPC). Despite the contributions of these large studies, new substitutions 
are still discovered with almost every new case that is analyzed. 
Up to 25% of newly diagnosed patients have high-risk PCa, meaning that they have a high risk of 
recurrence of the disease and a high risk of dying from PCa (Meng et al. 2005). High-risk patients are 
defined as having at least one of the following risk factors: PSA ≥ 20 ng/ml, biopsy Gleason score ≥ 8, 
clinical T-stage ≥ T2c (D'Amico et al. 1998). However, these patients have heterogeneous outcomes: 
not all patients have invariably poor prognoses and the challenge is to better define lethal PCa 
(Briganti et al. 2012). Therefore, we need to understand the underlying genetic changes that can 
diversify patients according to the aggressiveness of the disease. The present study focused only on 
high-risk PCa patients, in the hope it would eventually lead to novel classifications of PCa patients by 
adding genetic markers to the clinical diagnostics and prognostics.  
 
DNA methylation plays an important role in development, aging and disease. Indeed, the 
methylation of cytosine to methylcytosine (5mC) is so crucial that is has been called the fifth base in 
the genome. Despite the discovery of DNA methylation more than 60 years ago, and its known role in 
most processes involving the genome, the mechanisms controlling 5mC dynamics are only starting to 
being unraveled (Hotchkiss 1948). In 2009, TET1 (ten-eleven translocation 1) was identified as a 
dioxygenase that catalyzes the conversion of 5mC to 5-hydroxymethylcytosine (5hmC), also known as 
the sixth base (Tahiliani et al. 2009). The latter can be further oxidized to 5-formylcytosine (5fC) and 
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5-carboxylcytosine (5caC) (He et al. 2011, Ito et al. 2011). This led to the discovery that the activity of 
TET1, as well as the related TET2 and TET3 proteins, participate in active or passive DNA 
demethylation (Figure 5.1) (Guo et al. 2011). Passive demethylation of 5mC oxidation products can 
occur through cell division, while active demethylation consists of several steps including the 
oxidation of 5hmC to 5fC or 5caC or the deamination of 5hmC to 5hmU (5-hydroxymethyluracil) 
followed by the removal of these modified bases by base excision repair (BER).  
 
Figure 5.1. Involvement of TET family proteins in the regulation of DNA methylation and 
demethylation. Genomic 5mC can be removed passively during replication, but active demethylation 
has also been proposed. TET proteins convert 5mC to 5hmC, which can then be converted to 5hmU 
by AID/APOBEC enzymes. Consecutive action of TDG and BER result in an unmethylated cytosine. 
Abbreviations: DNMT, DNA methyl transferase; TET, ten-eleven translocation; AID, activation-
induced deaminase; APOBEC, apolipoprotein B mRNA-editing enzyme complex; TDG, thymine DNA 
glycosylase; BER, base excision repair.  
 
Patterns of DNA methylation are profoundly altered in human cancers. In particular, aberrant 
promoter hypermethylation leading to inappropriate transcriptional silencing of tumor suppressor 
genes and a global hypomethylation in intergenic regions are characteristic for cancer cells (Baylin et 
al. 2011). Loss of 5hmC has also been described in various solid tumors, including breast, colon, lung, 
kidney, and prostate cancer (Haffner et al. 2011, Jin et al. 2011, Kudo et al. 2012). Moreover, 
substantial downregulation of all three TET genes, but most significantly of TET1, has been described 
in colorectal, liver, breast and prostate cancers (Kudo et al. 2012, Yang et al. 2013). In particular, 33% 
of 153 PCa patients showed a reduced TET1 expression in cancer cells as compared to non-neoplastic 
glands (Hsu et al. 2012). Finally, TET1 has been shown to be an essential tumor suppressor in PCa and 
breast cancer through the downregulated methylation of critical genes such as TIMP2 and TIMP3 
(Hsu et al. 2012). Here we report a first mutation in the TET1 gene for high-risk PCa.  
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5.3. MATERIALS AND METHODS 
5.3.1. Materials 
Oligonucleotides were purchased from Integrated DNA Technologies. PCR reactions were performed 
on a Progene thermocycler using Expand High Fidelity PCR System (Roche Applied Science). All 
plasmid constructs were purified using the Qiagen Plasmid Midi kit (Qiagen) and analyzed by Sanger 
sequencing analysis at LGC Genomics. Antibodies used for dot blot, DIP-Seq and 
immunohistochemistry are antibodies against 5-methylcytosine (Eurogentec) and 5-
hydroxymethylcytosine (Active Motif).  
 
5.3.2. Plasmid constructs 
The luciferase reporter plasmid and the androgen receptor (AR) expression vector have been 
described before (Denayer et al. 2010). The classical ARE-regulated luciferase reporter plasmid was 
based on a pGEM-4Z vector that contains four copies of the SLP-MUT ARE, a minimal E1B-TATA box, 
and the pGL4 luciferase gene (Promega), all surrounded by chicken -globin insulators. The pCMV--
gal expression plasmid was obtained from Stratagene. Constructs containing the catalytic domain of 
TET1 in a pEF1 vector were a kind gift from Kian Koh (Stem Cell Biology and Embryology Laboratory, 
Department of Development and Regeneration, KU Leuven). Full length TET1 in pcDNA6.2 plasmids 
were a kind gift from Diether Lambrechts (Vesalius Research Center, KU Leuven).  
 
5.3.3. Prostate cancer sample acquisition 
High-risk primary prostate tumors were obtained under protocols approved by the KU Leuven Ethical 
Committee from consented patients undergoing radical prostatectomy. Matching germline DNA was 
derived either from histologically benign prostate tissue or peripheral blood cells. Specimens were 
collected at the University Hospitals of Leuven within the PEARL consortium (ProstatE cAncer 
Research team Leuven). After tissue homogenization and lysis, DNA was extracted and assessed for 
quality by Nanodrop and PicoGreen measurements.  
 
5.3.4. Copy number analyses 
Genome-wide SNP genotyping was performed using Illumina CytoSNP arrays on an iSCAN (Illumina). 
Processing of DNA samples, hybridization, staining, scanning of the BeadChips, and primary data 
extraction were all performed according to the Illumina Infinium protocol at the Vesalius Research 
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Center (Leuven, Belgium). GenomeStudio software was used for primary assessment of data and 
quality control assessment. The ASCAT (Allele-Specific Copy number Analysis of Tumors) software 
(version 2.1) was used to accurately determine allele-specific copy number alterations from SNP 
array data in solid tumors, while estimating and correcting for both tumor aneuploidy and infiltration 
of non-aberrant cells (Van Loo et al. 2010). To identify genomic regions that were significantly 
amplified or deleted, the Genomic Identification of Significant Targets in Cancer (GISTIC, version 
2.0.1) method was used, as previously described (Beroukhim et al. 2007).  
 
5.3.5. Exome sequencing 
The exome capture was performed using the SeqCap EZ Exome version 2 kit (Roche Nimblegen), after 
which paired-end sequences of 101 nucleotides were generated with an Illumina HiSeq2000 or 
HiSeq2500 instrument (Genomics Core, UZ Leuven). Sequencing data were aligned to the hg19 
human reference genome with BWA and processed by the Picard pipelines (Li et al. 2009a) 
(http://picard.sourceforge.net/). Alignment files were processed further with Genome Analysis 
Toolkit (GATK) before variant calling and included duplicate removal, local realignment around 
known indels and base quality recalibration (McKenna et al. 2010). Somatic point mutations were 
detected by comparison of tumor and paired normal exome sequences with MuTect and 
SomaticSniper (Cibulskis et al. 2013, Larson et al. 2012). Single nucleotide variants (SNVs) were 
annotated with the SeattleSeq tool (http://snp.gs.washington.edu/SeattleSeqAnnotation138/).  
 
5.3.6. Validation of point mutations 
Validation of somatic missense and nonsense variants in the tumor and matched normal genomes 
was performed either using standard Sequenom MassARRAY genotyping experiments or Sanger 
sequencing. Sequenom validation was performed according to the manufacturer’s conditions. 
Automated genotyping calls were generated using the MassARRAY RTTM software (Sequenom) and 
were validated by manual review of the raw mass spectra. The following approach was used: SNVs 
that failed to be successfully genotyped in the first round of validation were subsequently redesigned 
for a second attempt using a new set of Sequenom primers. When SNVs also failed to be successfully 
genotyped in this second round, they were considered as ‘failed genotyping using Sequenom’. The 
Sequenom validation experiment was performed at the Vesalius Research Center (Leuven, Belgium). 
We also carried out Sanger sequencing to try to validate SNVs that could not be validated by 
Sequenom. We therefore designed primers specific to the region containing the SNV to be tested 
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using the NCBI Primer-Blast (http://ncbi.nlm.nih.gov/tools/primer-blast/). Standard PCR reactions 
were sequenced and sequence trace files were analyzed using Chromas Lite.  
 
5.3.7. Cell culture and transfection studies 
HEK-293T cells were obtained from the American Type Culture Collection and grown at 37°C and 5% 
CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco). This medium was supplemented with 
100 µg/ml penicillin, 100 µg/ml streptomycin and 10% heat-inactivated fetal calf serum (FCS). For dot 
blot and western blot assays, HEK cells were seeded in a 6-well plate and transfected with the 
GeneJuice transfection reagent (Merck Millipore). For the coactivation studies, HEK cells were 
transfected with a mixture of 100 ng luciferase reporter plasmid (preceded by four copies of an ARE), 
10 ng AR expression vector, 10 ng TET1 and 10 ng pCMV--gal expression plasmid, which served as 
an internal control for transfection efficiency. On day 1, cells were seeded in a 96-well plate in DMEM 
containing 5% dextran-coated charcoal-stripped fetal calf serum. The next day, the cells were 
transfected with the GeneJuice transfection reagent. On day three, the medium was replaced and 
cells were stimulated with vehicle or with 10 nM of the synthetic ligand methyltrienolone (R1881, 
Perkin-Elmer, Life Sciences). After 24 hours of stimulation, the cells were harvested in Passive Lysis 
Buffer (Promega). Luciferase and -galactosidase activity was measured as described before (Haelens 
et al. 2001). The relative luciferase activities represent the amount of chemiluminescence corrected 
for the transfection efficiency by normalizing against the -galactosidase activity. The values shown 
are the averages of at least three independent experiments performed in triplicate.  
 
5.3.8. (h)MEDIP-SEQ 
Three µg of genomic DNA was fragmented to 100-500 bp using the Diagenode bioruptor, end 
repaired and A-tailed. Following a purification step with dynabeads (Dynal Biotech), sequencing 
adapters were ligated. For the enrichment step of the methylated DNA immunoprecipitation, 5 µl of 
an anti-5-methylcytosine antibody or 3 µl of an anti-5-hydroxymethylcytosine antibody coupled to 
magnetic beads were used. Antibody binding was conducted by overnight incubation in IP buffer (1x 
PBS, 0.5% BSA, 0.05% Triton X-100). After two hours of incubation with protein A/G magnetic beads 
(Pierce), the captured samples were washed and bound DNA was eluted by heating the beads for 10 
minutes at 99°C. The eluted DNA was amplified by 14 cycles of PCR using Illumina primers, purified 
and the quality was checked using Picogreen, Nanodrop and BioAnalyzer. Sequencing was performed 
on the HiSeq2000 (Illumina) as 50 bp, single-end reads. Sequence reads were aligned to the human 
reference genome (hg19) using Bowtie with –m 1 --strata –best as parameters (this means that only 
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1 mismatch is allowed, uniquely mapped reads are retained and only the alignment with the best 
score is reported in case of multiple alignment) (Langmead et al. 2009). Model-based Analysis of 
ChIP-Seq (MACS) was used as the peak-finding algorithm using input DNA as a background control, 
and after in silico extension of the reads by 100 bp (Zhang et al. 2008). The entire DIP-Seq protocol 
and the analyses were performed at the Vesalius Research Center (Leuven, Belgium). GO term and 
KEGG pathway analyses were performed by the database for annotation, visualization, and 
integrated discovery (DAVID) programs (Huang da et al. 2009a, Huang da et al. 2009b).  
 
5.3.9. Western blot 
From a cell pellet, whole cell extracts were prepared in HEPES extraction buffer (25 mM HEPES, 300 
mM NaCl, 1.5 mM MgCl2, 20 mM -glycerolphosphate, 2 mM EDTA, 2 mM EGTA, 1 mM DTT, 1% 
Triton X-100, 10% glycerol, 1 mM Na3VO4, 50 mM NaF and protease inhibitors) by three freeze-thaw 
cycli. Fifty µg extract per lane was loaded on NuPage Novex 4-12% Bis-Tris Gels (Life Technologies) 
and blotted onto PVDF membranes (GE Healthcare). The membranes were probed with the 
appropriate primary and secondary antibodies (TET1, 1:100; GAPDH, 1:200; both from Santa Cruz 
Biotechnology), and immunoreactive proteins were visualized by enhanced chemiluminescence 
(Western Lightning Plus-ECL, Perkin Elmer).  
 
5.3.10. Dot blot 
Genomic DNA was isolated using the GenElute Mammalian Genomic DNA Miniprep kit (Sigma-
Aldrich). DNA containing 5C, 5mC and 5hmC (Active Motif) were used as controls. Serial dilutions of 
the DNA were prepared in denaturation buffer (0.4 M NaOH and 10 mM EDTA) and denatured for 10 
minutes at 99°. The samples were chilled on ice and neutralized with an equal volume of ice-cold 2 M 
ammonium acetate. Meanwhile, the membrane was activated in distilled water (Zeta probe blotting 
membrane, Biorad). After sample loading, the membrane was washed with 0.4 M NaOH and 2x SSC. 
The DNA was then UV cross-linked to the membrane (UV Light Stratalinker 1800). The membrane 
was blocked for 1 hour in TBST (Tris-buffered saline containing 0.1% Tween 20) and then probed with 
the appropriate primary and secondary antibodies (5hmC, 1/1000; 5mC, 1/2000). Modified bases 
were visualized by enhanced chemiluminescence (Western Lightning Plus-ECL, Perkin Elmer).  
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5.3.11. Immunohistochemistry 
Paraffin-embedded formalin-fixed (FFPE) sections were used for immunohistochemical stainings on 
33 PCa samples. Antigen recovery was performed in citrate buffer pH 6 for 20 minutes, followed by 
incubation with the primary ERG rabbit monoclonal antibody (Abcam), used in a 1:100 dilution. 
Incubation with the secondary antibody, DAB staining and hematoxylin counterstaining were 
performed with the BOND polymer refine detection system (Leica). Immunohistochemical stainings 
were performed on the Bond Max Autostainer (Leica) in collaboration with the Pathology 
Department of UZ Leuven. 
 
 
5.4. RESULTS 
5.4.1. Leuven high-risk cohort 
Our cohort consists of 34 patients diagnosed with high-risk PCa and treated with radical 
prostatectomy. Biological samples were obtained within the frame of the PEARL consortium 
(ProstatE cAncer Research team Leuven). Tumor samples with at least 50% tumor content were used 
for copy number profiling, while samples containing at least 75% tumor content were used for both 
copy number profiling and exome sequencing. Tumor content was estimated by one pathologist 
(Prof. E. Lerut, Pathology department UZ Leuven). Clinical characteristics of the patients can be found 
in Supplementary table 5.1, while Supplementary table 5.2. gives an overview of which samples have 
been used for the different experiments that were performed.  
 
5.4.2. Copy number profiling 
5.4.2.1. Detection of amplified and deleted regions 
Analysis of the copy number changes of 32 patients was performed with a combination of the ASCAT 
and GISTIC software. Four samples failed to give any results, presumably due to low tumor 
percentage. Another sample could be analyzed, but did not present with any copy number alteration. 
A representative example of a tumor genome for which copy numbers were determined by ASCAT is 
shown in Supplementary figure 5.1. We identified regions of recurrent copy number alterations using 
GISTIC, revealing 12 amplifications and 14 deletions (Figure 5.2). The loss of 8p (containing NKX3.1) 
and gain of 8q (containing MYC) were recurrent. Other peaks of deletion targeting PTEN (10q23.31) 
and RB1 (13q14.2) were identified. The deletion of TMPRSS2 (21q22.2) resulting in the fusion of ERG 
with TMPRSS2 was detected in 11 of the 28 samples. An amplified peak targeting NKX6.2 was also 
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detected on 10q26.3. All of our recurrently deleted regions have been described before in PCa, while 
we detected one amplified region that has not been described before in PCa: 7p22.3. It remains to be 
defined which of the genes contained within this region might be causal oncogenes.  
The TMPRSS2-ERG fusion is by far the most common rearrangement in any neoplasm, since it has 
been detected in almost 50% of all PCa cases examined (Perner et al. 2007). Initially, GISTIC analysis 
was performed on the whole cohort of 28 tumors, but subsequently a GISTIC analysis was also 
performed on the subgoups. The classification was based on a deletion of the TMPRSS2 gene as 
determined from the copy number data and ERG overexpression as determined with 
immunohistochemical staining. We performed a subgroup analysis of 17 patients without TMPRSS2 
deletion and 11 patients with deletion of TMPRSS2. We did not find differences in the number of 
copy number alterations when comparing both groups (data not shown).  
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Figure 5.2. Significant copy number alterations in the genomes of high-risk PCa. A. Amplifications 
(red) and deletions (blue) are displayed across the genome (chromosome positions, indicated along 
the y axis, are proportional to marker density) of 28 PCa samples. Each column represents a single 
tumor sample. B. GISTIC analysis of copy number changes in PCa. The statistical significance of the 
aberrations identified in A are displayed as false-discovery rate q values to account for multiple-
hypothesis testing. Chromosome positions are indicated along the y axis. Twelve amplifications and 
14 deletions surpass the significance threshold (green line). The locations of the peak regions are 
indicated next to each panel. Processing and primary data extraction were performed at the Vesalius 
Research Center.  
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5.4.2.2. Detection of ERG overexpression using immunohistochemistry 
It has been described before that the TMPRSS2-ERG fusion can be detected with 
immunohistochemistry instead of with FISH (Park et al. 2010). The assay of Park and colleagues had 
95.7% sensitivity and 96.5% specificity for detecting the ERG gene fusion in PCa with 
immunohistochemistry. We wanted to investigate whether this immunoassay also works in our 
hands, and whether it correlates with the findings of the copy number profiling. Copy number 
analyses detected a deletion of TMPRSS2 in 11 out of 28 patients. These 11 were confirmed using 
immunohistochemistry (Figure 5.3). However, in a total of 33 patients, we detected an additional 14 
patients of which (part of) the tumor presented with ERG overexpression.  
 
Figure 5.3. Representative picture of ERG immunohistochemical staining. The prostate contained 
tumor foci with and without ERG overexpression. A. Tumor focus without ERG overexpression. B. 
Tumor focus with ERG overexpression. Non-tumoral tissue without ERG overexpression can be 
observed in the upper left and lower right corner. Endothelial cells were used as internal positive 
control. Images of sample 88824362 were taken at 10x objective magnification.  
 
5.4.3. Exome sequencing  
5.4.3.1. Detection of point mutations using exome sequencing 
Whole exome sequencing using 100 bp paired-end reads was performed on 27 samples of which the 
tumor content was at least 75% as estimated by the pathologist. On average, 118 million reads were 
sequenced per sample, with 86% of target bases covered at a depth of ≥20x (Supplementary table 
5.3). For variant calling, we used a combination of MuTect and SomaticSniper. We then focused on 
missense and nonsense mutations that are not present in dbSNP132. Finally, we only retained those 
mutations that are present in at least 10% of tumor reads, and in less than 2% of non-tumor reads. 
This led to the identification of 947 somatic mutations that were present in DNA from tumors but 
absent in DNA from peripheral blood or non-cancerous prostate tissue (Supplementary table 5.4). Of 
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these, 451 occurred in a single tumor. We hypothesize that a mutation in the Replication Factor C 
(RFC1) gene could impair DNA repair, resulting in a hypermutated phenotype. Excluding this highly 
mutated sample, we detected 496 point mutations in 442 different genes. The remaining tumors 
harbored a median of 19 missense or nonsense mutations (range of 1 to 37 mutations) (Figure 5.4). 
In one of the 27 samples, we could not detect any point mutation, nor could we detect any change in 
copy number. We thus propose that this sample either contained a too low amount of tumor cells, or 
that the tumorigenic process is regulated by epigenetic and translational changes.  
 
Figure 5.4. Histogram for 27 patient samples showing the number of point mutations detected with 
exome sequencing. One hypermutated samples contains 451 mutations (UR1562), while all the other 
samples contain 19 mutations on average.  
 
5.4.3.2. Validation of mutations 
As we used both the MuTect and the SomaticSniper algorithm to call variants, our final list contains 
mutations that are detected either with both algorithms, or with only one algorithm. A combination 
of Sanger sequencing and mass spectrometry genotyping was used to validate the detected 
mutations. To ensure a somatic origin of the variants, both germline and tumor DNA were 
investigated. A PCR-based amplification of the exonic regions containing the mutations followed by 
conventional Sanger sequencing was performed for 40 mutations, while mass spectrometry 
evaluated 314 mutations. In total, 354 mutations were analyzed and 79.4% of variants were 
validated.  
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5.4.3.3. Recurrently mutated genes 
We detected 947 mutations in 831 different genes. Of these genes, seventeen are recurrently 
mutated in our high-risk PCa cohort (Figure 5.5). It should be noted that the majority of these 
recurrently mutated genes still needs validation with Sequenom or Sanger sequencing.  
Figure 5.5. Representation of recurrently mutated genes, colored by the coding consequence of the 
mutation. Each column represents a tumor, and each row represents a gene.  
 
5.4.4. Mutation in TET1 causes partial loss of function 
In the exome of one of our patients, we detected a A1908S mutation in the TET1 gene. Knowing that 
DNA methylation is perturbed in almost all cancers and that TET1 is involved in the demethylation 
process, we wanted to investigate whether this mutation, which is localized in the catalytic domain 
of TET1, would have a detrimental effect on the enzymatic activity of TET1 (Figure 5.6.A).  
 
5.4.4.1. Reduced activity of overexpressed mutant TET1 
We first performed a dot blot assay for 5hmC on DNA derived from tumoral and non-tumoral tissue 
of the patient with the A1908S mutation in the TET1 gene. Indeed, the tumoral tissue presented with 
a decreased amount of 5hmC compared to non-tumoral tissue (Figure 5.6.B). However, loss of 5hmC 
is detected in many solid tumors and can be attributed to different causes. We therefore specifically 
wanted to test the enzymatic activity of A1908S TET1. We overexpressed the catalytic domain of wild 
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type TET1 in HEK cells, as well as the catalytically inactive mutant (mHxD, H1672Y and D1674A), the 
A1908S mutant, and the vector only control (Figure 5.6.C). We observed a global increase of 5hmC 
levels in TET1 overexpressing cells, but not in the mHxD TET1 overexpressing cells. For the A1908S 
mutant, 5hmC is still formed, but to a lesser extent than in wild type TET1 overexpressing cells. 
Conversely, 5mC accumulates when mHxD TET1 is overexpressed, while no 5mC remains when wild 
type TET1 is overexpressed. Again, the level of 5mC present in the A1908S TET1 overexpressing cells, 
lies somewhere between that of the wild type and that of the mHxD mutant TET1. The 
overexpression of TET1 was verified by western blot and a similar level of expression for the different 
TET1 constructs was detected (Figure 5.6.D). Together, these data suggest that the decrease of 5hmC 
in this patient’s tumor is attributable to a decrease in TET1 activity, due to the presence of the 
A1908S mutation.  
 
Figure 5.6. Overexpression of the A1908S TET1 mutation demonstrates partial loss of the TET1 
enzymatic activity. A. Schematic diagram of full length TET1 and the catalytic domain of TET1 with 
the mHxD and A1908S mutations. B. Dot blotting shows that the 5hmC level is decreased in tumoral 
tissue. Genomic DNA isolated from tumoral and non-tumoral tissue of the patient with the TET1 
mutation was serially diluted. DNA that contains only 5mC or 5hmC was used as negative and 
positive control respectively. C. Dot blot assay with serial dilutions of DNA, demonstrating global 5mC 
and 5hmC levels in HEK cells that overexpress the empty control vector, wild type TET1, catalytically 
dead mHxD mutant or the A1908S mutation. D. The expression of TET1 protein by western blot. The 
same conditions were used as in the dot blot experiment. GAPDH was used as loading control.  
Genomic analysis of high-risk prostate cancer 
 
87 
 
5.4.4.2. Genome-wide mapping of 5mC and 5hmC 
We next asked whether the 5hmC loss in the patient’s tumor as determined by dot blot assay was 
genome-wide or locus-specific. We investigated the 5hmC and 5mC level changes by mapping the 
genome-wide 5hmC and 5mC distribution using a hydroxymethylated DNA immunoprecipitation 
(hMeDIP) or a methylated DNA immunoprecipitation (MeDIP) approach coupled with deep 
sequencing (hMeDIP-Seq and MeDIP-Seq). We compared DNA from the patient’s tumoral and non-
tumoral tissue with DNA from two other PCa patients without mutations in the TET1 gene. The 
sample with the TET1 mutation also has a deletion of the PTEN gene as determined by copy number 
changes and ERG overexpression as determined with immunohistochemistry. The two other samples 
do not have any of the common features in PCa (such as PTEN deletion, SPOP or TP53 mutation) 
except for ERG overexpression. Compared to the two tumor samples with wild type TET1, the 
mutated sample displayed the strongest overall hypo-hydroxymethylation. The present results 
strongly provide evidence that the 5hmC loss is a genome-wide event and that the TET1 mutation 
had an effect in the affected cancer tissue (Figure 5.7). Because 5hmC is converted from 5mC by TET 
enzymes, we reasoned that the decreased 5hmC generation would result in the accumulation of its 
substrate, 5mC. Indeed, we observed a relative hypermethylation at specific loci. As exemplified in 
Supplementary figure 5.2, KLK2 and SLC45A3 genes show decreased 5hmC in gene bodies in the 
tumor sample with mutated TET1 compared with the non-tumoral prostate of the same patient.  
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Figure 5.7. Genome-wide results for MeDIP-Seq en hMeDIP-Seq. Immunoprecipitation of methylated 
and hydroxymethylated DNA followed by deep sequencing was performed on DNA isolated from the 
tumoral and non-tumoral tissues of three patients with PCa. One patient (Sample 3 MUT, 88824362) 
had the A1908S mutation in TET1, while the other 2 patients (UR1554 and UR1568) did not have a 
mutation in TET1. An overall decrease in 5hmC and an increase in 5mC at specific loci was observed 
in the tumor with mutated TET1. The protocol and analyses were performed at the Vesalius Research 
Center.  
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5.4.4.3. Interplay between androgens and 5hmC 
By manually reviewing the hMeDIP-Seq data of the patient with the A1908S TET1 mutation, we 
noticed that there seemed to be a drastic decrease in 5hmC in some androgen-regulated genes. To 
explore this more systematically, we gathered a list of 323 androgen-regulated genes. Each of these 
genes has been detected in at least 2 independent studies as being androgen-regulated (Rajan et al. 
2011). As can be observed in Figure 5.8, a substantial subset of gene bodies of these genes are 
indeed hypo-hydroxymethylated in the tumoral tissue of the patient with the TET1 mutation. We 
generated a list of 55 androgen-regulated genes in which the hydroxymethylation in the tumor is 
substantially lower than in the non-tumoral tissue of the same patient, or in the tumoral tissues of 
the two other patients with wild type TET1. KEGG pathway enrichment analysis for the 55 genes 
revealed that these genes are closely associated with pathways regulating peptidase and protease 
activity, positive regulation of transcription and gene expression, and positive regulation of apoptosis 
and cell death.   
 
Figure 5.8. Genome-wide results for MeDIP-Seq and hMeDIP-Seq of 323 androgen-regulated genes. 
Immunoprecipitation of methylated and hydroxymethylated DNA followed by deep sequencing was 
performed on DNA isolated from the tumoral and non-tumoral tissues of three patients with PCa. 
One patient (Sample 3 MUT, 88824362) had the A1908S mutation in TET1, while the other 2 patients 
(UR1554 and UR1568) did not have a mutation in TET1.  
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5.4.4.4. TET1 is a coactivator of the androgen receptor 
The DIP-Seq experiments showed us that multiple androgen-regulated genes displayed less 5hmC 
both in the gene body and in the promoter of the sample with the A1908S TET1 mutation. We 
wanted to investigate whether TET1 can influence the activity of the androgen receptor as a 
transcription factor. We therefore performed AR coactivation experiments: in the presence of the 
ligand R1881, an active AR binds to an androgen response element (ARE) which will then result in the 
activation of the nearby luciferase reporter. In the absence of R1881, luciferase will not be 
expressed. The addition of increasing amounts of wild type, full length TET1 resulted in an increasing 
luciferase activity, indicating that TET1 is indeed a coactivator of the AR (Figure 5.9.A).  
Figure 5.9. TET1 is a coactivator of the androgen receptor. A. HEK-293T cells were transfected with 
100 ng luciferase reporter, 10 ng of AR and pCMV--gal each, and increasing amounts of TET1. The 
next day, cells were incubated in the absence or presence of 10 nM R1881. After 24 hours of 
stimulation, luciferase and -galactosidase activities were measured. The relative luciferase activity 
represents the amount of luminescence corrected for the transfection efficiency by normalizing 
against -galactosidase activity. The values shown are the averages of at least 3 independent 
experiments performed in triplicate. Error bars indicate SEM values. Values that are significantly 
different compared to the value without TET1 are signalized with a * (p<0.05; student’s t-test). B. 
Similar experiment as in A, except that 10 ng of different TET1 constructs (wild type, mHxD and 
A1908S) are transfected in HEK-293T cells.  
 
Knowing that TET1 is a coactivator of the androgen receptor, and that our A1908S mutant showed a 
decreased enzymatic activity in dot blot assays and hMeDIP-Seq experiments, we wondered whether 
the mutated TET1 would also result in a decreased coactivation. When the catalytically dead mHxD 
TET1 is overexpressed, no coactivation is detected (Figure 5.9.B). The overexpression of A1908S TET1 
resulted in a tendency to a decreased coactivation compared with the activity of the wild type TET1.  
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5.5. DISCUSSION 
Barbieri et al. reported the first exome analyses of a cohort of 112 primary PCa samples (Barbieri et 
al. 2012). However, this cohort was very heterogeneous in tumor staging, Gleason grading and 
predicted risk of recurrence. Here, we sequence a more homogeneous cohort of 27 patients that are 
predicted to have a high risk of recurrence, as predicted by the d’Amico risk group (D'Amico et al. 
1998).  
 
5.5.1. Copy number profiling 
5.5.1.1. Copy number changes detected in high-risk prostate cancer 
Using SNP arrays, we identified several recurrently amplified and deleted regions in the genomes of 
primary high-risk prostate cancers. Most of the amplifications and deletions have been described 
before for the combination of low, intermediate and high-risk PCa (Barbieri et al. 2012, Taylor et al. 
2010). However, we detected a novel amplification of the 7p22.3 region which hasn’t been described 
before. It is possible that one or more oncogenes within this region play an important role specifically 
in high-risk PCa. To be able to pinpoint the possible oncogenes in these regions, larger cohorts are 
needed. As the number of analyzed samples increases, the regions will become smaller, and it will 
become easier to identify the causal oncogenes.  
 
5.5.1.2. TMPRSS2-ERG fusion as detected by copy number and ERG overexpression 
Discordances between the TMPRSS2-ERG fusion status as derived from copy number profiling and 
ERG overexpression can have different reasons. First of all, in the case of TMPRSS2-ERG, the 
rearrangement occurs either by a 3 megabase interstitial deletion on a single copy of chromosome 
21, or by a chromosomal translocation. Copy number analyses will only identify the fusion when 
formed by a deletion, while ERG overexpression as detected by immunohistochemistry can be the 
result of the fusion formed either by deletion or chromosomal translocation. Secondly, ERG 
overexpression can result not only from a fusion with TMPRSS2, but can also be fused to other genes 
like SLC45A3 or NDRG1 (Han et al. 2008, Pflueger et al. 2009). This will result in overexpression of 
ERG as detected with immunohistochemistry, while this would be undetected by copy number 
changes. Finally, the biopsy core used for the copy number analyses probably contained only one 
tumor focus while the ERG overexpression was assessed on sections containing the entire prostate 
(with multiple foci). Ideally, FISH data and RT-PCR data should be used to unequivocally determine 
the presence or absence of the TMPRSS2-ERG fusion, but these assays have not been performed in 
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this study. Nowadays, FISH is still considered to be the gold standard to identify ERG rearrangement, 
but recent studies provided convincing evidence that the immunohistochemical staining of ERG can 
be used as a surrogate for the more difficult FISH (Svensson et al. 2014). 
 
5.5.2. Exome sequencing data 
5.5.2.1. Recurrently mutated genes 
Exome sequencing was performed on 27 cases of primary high-risk PCa. Several of the recurrent 
mutations in this study have been detected in other cohorts (Barbieri et al. 2012, Lindberg et al. 
2012). Mutations in SPOP, TP53, and PTEN have been reported to occur in 13%, 6% and 4% of PCa 
samples respectively (Barbieri et al. 2012). Recurring mutations in the MLL3 gene were detected in 
8% of PCa patients (Lindberg et al. 2012). Some of the recurrent mutations in our list, like APOB have 
not been reported yet, but need confirmation. Indeed, since they occur in genes that are part of large 
gene families, they might be explained by misalignments of reads rather than genuine mutations. 
Surprisingly, about half of the mutated genes we detected (200 out of 442 genes) have not been 
described in high-risk PCa yet. It seems that the more samples will be sequenced, the more likely rare 
mutations or non-recurrent mutations will be picked up. This is a strong indication of the genetic 
heterogeneity of the disease. Moreover, some of our novel recurrently mutated genes could well be 
genes that distinguish between low-risk and high-risk PCa.  
 
5.5.2.2. Mutation in RFC1 could result in a hypermutated tumor 
On average, each sample contains 19 point mutations. One sample however contained 451 
mutations. One of these 451 was a mutation in the RFC1 gene to which several functions have been 
ascribed. The eukaryotic sliding DNA clamp, proliferating cell nuclear antigen (PCNA), is essential for 
DNA repair synthesis. In order to load PCNA onto the DNA double helix, the ATPase activity of the 
RFC clamp loader complex is required (Hashiguchi et al. 2007). This complex consists of five subunits, 
of which RFC1 is the large subunit. RFC1 is dispensable for recruitment of PCNA to damaged DNA, yet 
it is required for the subsequent recruitment of DNA polymerase delta to PCNA. This indicates that 
RFC1 is essential to stably load the polymerase clamp to enable the start of DNA repair synthesis. The 
detected mutation in RFC1 could result in an impaired loading of DNA polymerase, leading to 
impaired DNA repair synthesis and resulting in the almost 500 point mutations. Further studies are 
required to test this hypothesis.  
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5.5.2.3. Molecular classification of prostate cancer 
Large scale integration of copy number aberrations and mutations derived from systematic 
sequencing studies have led to the definition of molecular subclasses of PCa (Barbieri et al. 2013). 
This classification might signal the start of the transition of PCa from a poorly understood and 
clinically very heterogeneous disease, to a collection of homogeneous subtypes that are identified by 
molecular features (Figure 5.10.A). Each genomic subclass might have a distinct prognosis, and 
hopefully at some point will be treatable with specific targeted therapies. So far, the classification is 
based on the following features:  
- The TMPRSS2-ERG fusion which is present in about half of all PCa patients 
- Inactivation of the tumor suppressors PTEN and/or TP53 achieved through point mutations or copy 
number deletions (in about 30%)  
- SPOP mutations, frequently co-occurring with deletion of the CHD1 gene.  
A more detailed classification is needed: in our cohort, 9 out of 27 patients cannot be classified into 
any of these subtypes (Figure 5.10.B). This suggests that the disease is genetically heterogeneous. 
Maybe these 9 cases should be put in one class of tumors having infrequently mutated genes and the 
patients might need personalized treatments at later stages of the disease. Indeed, we and others 
discovered many unique mutations in genes that might be part of signal transduction pathways that 
are druggable targets.  
Moreover, it is also important to study the individual mutations. Indeed, in the case of TET1, a 
C1746F mutation was reported by Lindberg and colleagues (Lindberg et al. 2012). In our dot blot 
assays and western blots, this mutant had no effect on the enzymatic activity of TET1 (data not 
shown). 
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Figure 5.10. Molecular classification of high-risk PCa. A. About half of all primary PCas harbor 
TMPRSS2-ERG fusions. The PTEN and TP53 tumor suppressors are deleted or mutated in 20-40% of 
primary PCa, with significant overlap with each other and with the fusion. SPOP mutations occur in 
about 10% of all PCas and are mutually exclusive with the fusion, while they are associated with 
deletions of CHD1. Picture taken from (Barbieri et al. 2013). B. Same classification as in A, but applied 
to our 27 high-risk PCa samples. TMPRSS2-ERG means that a deletion of TMPRSS2 was detected 
using copy number analyses.  
 
5.5.2.4. Future perspectives for the high-risk Leuven cohort 
Our current cohort of 34 patients is constantly expanding, with new patients included every month. 
This however also means that we do not have long-term follow-up or outcome of individual patients 
yet. Nevertheless, we still feel that our cohort is informative, as it is homogeneous and only contains 
patients that are predicted to have a high risk of recurrence. Having identified mutated genes in 
every patient, we know that the number of mutations per patient in our cohort is similar as 
compared to cohorts consisting of a mix of low-, intermediate- and high-risk patients. Moreover, we 
were able to identify interesting, novel mutations that have not been implicated in PCa before. 
Examples are the A1908S mutation in TET1 and the mutation in the RFC1 gene which is involved in 
the DNA repair processes.  
 
 
 
 
 
Genomic analysis of high-risk prostate cancer 
 
95 
 
5.5.3. Identification of a mutation in TET1 in prostate cancer 
5.5.3.1. Possible mechanisms for the loss of TET1 activity in prostate cancer 
Mammalian cells express three TET genes: TET1, TET2 and TET3. Mutations in TET2 that impair 
enzymatic activity have been reported frequently in various myeloid leukemias. For example, around 
20% of patients with acute myeloid leukemia have a mutation in the TET2 gene (Shih et al. 2012). For 
PCa however, no mutations in TET1 or TET2 have been explicitly described before. A literature study 
of next-generation sequencing studies on prostate cancer samples revealed two mutations in TET1. A 
C1746F mutation in the catalytic domain of TET1 as described by Lindberg et al. (see also point 
5.5.2.3.) and a P204H mutation in a high-risk PCa patient as described by Baca et al. (Baca et al. 2013, 
Lindberg et al. 2012). We don’t think this mutation has a functional effect, as it is located in the N-
terminal domain of TET1. Nevertheless, a profound reduction in 5hmC was observed in 30 PCa 
samples (Haffner et al. 2011). Haffner and colleagues did not define their cohort, neither did they 
report the actual number of samples that contains a reduction in 5hmC. This almost universal 
reduction of 5hmC levels in PCa can have different causes. First of all, copy number deletion of the 
region containing a TET gene could result in a downregulation of TET activity. In our cohort, two 
samples (UR1551 and UR1611) have a deletion in the 10q21.3 region that contains the TET1 gene. 
Next, TET1 enzymatic activity can also be inhibited by the reduction of alpha-ketoglutarate and 
accumulation of oncogenic metabolites such as 2-hydroxyglutarate resulting from mutations in IDH1 
or IDH2 enzymes (isocitrate dehydrogenase) (Xu et al. 2011). However, no such mutations in the 
IDH1 or IDH2 genes have been described in PCa. Finally, we hypothesize that a missense mutation or 
transcriptional inactivation of TET1 gene expression could result in a decreased enzymatic activity. 
Also changes in the activity of enzymes that methylate cytosine (DNA methyl transferases) and 
enzymes that remove 5hmC intermediates such as TDG and AID can cause the loss of 5hmC in cancer 
cells (Cadet et al. 2013). Thus, cancer-specific metabolic perturbations can influence 5hmC levels 
and, consequently, alter the epigenetic makeup of the cell (Figueroa et al. 2010, Xu et al. 2011). In 
the present study, we identified the first mutation in TET1 in PCa, and in solid tumors in general, that 
results in a partial loss of enzymatic activity.  
 
5.5.3.2. A1908S mutation in TET1 decreases its enzymatic activity 
Because the TET1 mutation impaired its enzymatic activity in vitro (Figure 5.6), we decided to 
perform a whole genome MeDIP- and hMeDIP-seq experiment on the remaining DNA purified from 
the tumor sample. Using (h)MeDIP-Seq, we did not find simple correlations between significant loss 
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of 5hmC, increases of 5mC and expression of associated genes as insufficient material was present to 
do transcriptome analyses.   
The two samples we choose as controls for the (h)MeDIP-Seq experiment seem to have lower 5mC 
and higher 5hmC compared to the TET1 mutant sample. As TET1 has been described to be less 
expressed in 33% of primary PCa, it will be crucial to know the TET1 expression status of all our 
samples (Hsu et al. 2012). Therefore, we are currently optimizing immunohistochemical stainings for 
TET1, 5hmC and 5mC to unequivocally detect the expression levels in both tumoral and non-tumoral 
tissue.  
 
5.5.3.3. Future challenges for the TET1 mutation 
Understanding the intricate relationship between regulation of 5hmC and associated gene 
transcription remains a challenge for future basic research. Furthermore, the interplay between 
androgens and TET1 needs further investigation. Since transfecting full length TET1 is technically 
challenging, we need to develop alternative approaches to unequivocally prove that TET1 is indeed a 
coactivator of the androgen receptor. This remains an important issue because of the crucial role of 
the AR in PCa development and treatments.  
Studies have identified TIMP2, TIMP3 and HOXA9 as downstream target genes of TET1, so this could 
be used to check the functional consequences of the mutated TET1 (Hsu et al. 2012, Sun et al. 2013). 
Moreover, a knockdown of TET1 in LNCaP cells results in more aggressive and more invasive tumors, 
eventually leading to a more metastatic phenotype. Expressing the mutant versus wild type TET1 in 
these LNCaP cells could also indicate the functional consequences of the mutation.   
In conclusion, we detected a novel A1908S mutation in the TET1 gene which causes a partial loss of 
enzymatic activity. What the consequences are for this individual tumor in terms of aggressiveness, 
metastatic capacity or biochemical recurrence, remains to be determined. 
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5.7. SUPPLEMENTARY INFORMATION 
 
Supplementary table 5.1. Clinical characteristics of prostate cancer genomes.  
Supplementary table 5.2. Overview of which samples have been used for certain experiments. 
Supplementary table 5.3. Summary of alignment results over 27 samples. 
Supplementary table 5.4. List of all 519 detected somatic point mutations. The table is not included 
in this thesis due to space constraints.  
 
 
 
Supplementary figure 5.1. A representative example of a tumor genome for which copy numbers 
were determined by ASCAT. 
Supplementary figure 5.2. MeDIP-Seq and hMeDIP-Seq results of KLK2 and SLC45A3 genes.  
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Supplementary table 5.1. Clinical characteristics of prostate cancer genomes.  
      
Positive 
  
   
Gleason Pathological PSA surgical  Last follow up 
Sample Date of RP Age score stage (ng/ml) margins Date PSA 
V2490 8/11/2011 51 4+3 T3aN1 24,75 0 15/01/2014 0 
88824362 17/11/2011 63 4+3 T3aN0 10,30 0 5/12/2013 0 
75247072 5/12/2011 65 4+4 T3aN0 7,90 0 11/10/2013 0 
UR1526 5/06/2012 51 4+3 T3bN1 27,00 0 6/01/2014 0 
UR1528 18/06/2012 63 4+3 T3aN1 10,00 0 12/12/2013 0,03 
UR1551 17/10/2012 62 3+4 T3aN0 6,10 0 7/10/2013 0 
UR1552 29/10/2012 56 3+4 T3aN0 30,22 0 12/09/2013 0 
UR1554 5/11/2012 65 3+4 T3aN0 8,95 0 18/10/2013 0 
UR1556 12/11/2012 64 3+4 T2cN0 4,58 0 12/12/2013 0 
UR1560 3/12/2012 71 4+4 T3aN0 15,64 0 29/07/2013 0 
UR1562 13/12/2012 74 4+5 T3bN0 5,99 0 18/09/2013 0 
UR1566 17/01/2013 69 4+3 T3aN0 5,20 1 6/11/2013 0 
UR1568 21/01/2013 62 3+4 T2cN0 5,10 1 2/01/2014 0,05 
UR1569 24/01/2013 63 4+3 T2cN0 4,66 0 20/01/2014 0 
UR1570 25/01/2013 74 4+5 T3aN1 19,00 1 28/05/2013 0,08 
UR1571 31/01/2013 62 4+4 T3bN0 28,00 1 6/01/2014 0 
UR1577 21/03/2013 75 4+5 T3bN0 10,90 0 30/01/2014 0 
UR1579 25/03/2013 67 3+4 T3aN0 6,70 1 6/01/2014 0 
UR1581 4/04/2013 69 4+3 T3aN0 18,00 1 30/01/2014 0 
UR1583 18/04/2013 65 4+5 T3bN1 15,20 1 6/01/2014 0,72 
UR1586 30/05/2013 67 4+3 T3aN0 4,16 0 10/01/2014 0,04 
UR1587 31/05/2013 56 4+3 T2cN0 10,60 0 30/01/2014 0 
UR1591 21/06/2013 62 3+4 T2cN0 15,00 0 12/12/2013 0,003 
UR1593 27/06/2013 73 3+4 T2cN0 9,50 0 4/12/2013 0 
UR1602 1/08/2013 63 5+4 T4N1 9,26 1 8/01/2014 0 
UR1603 12/08/2013 67 4+3 T3aN0 10,40 0 3/01/2014 0 
UR1605 29/08/2013 73 3+4 T3aN0 7,00 0 23/01/2014 0 
UR1606 30/08/2013 73 4+3 T2cN0 4,80 1 
  UR1607 9/09/2013 63 3+4 T2cN0 2,49 0 23/12/2013 0 
UR1608 16/09/2013 67 5+4 T3bN1 8,00 0 31/10/2013 0 
UR1611 3/10/2013 61 4+3 T3aN0 1,36 0 7/11/2013 0,07 
UR1615 31/10/2013 68 3+4 T3bN0 5,38 0 19/12/2013 0 
UR1616 4/11/2013 55 4+4 T3bN1 21,68 0 19/12/2013 0,14 
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Supplementary table 5.2. Overview of which samples have been used for certain experiments. Gray 
and light gray samples have been used for the corresponding experiments, but results could only be 
obtained for the green samples.  
Copy number 
alterations 
Whole exome 
sequencing 
Sequenom 
validation DIP-SEQ IHC ERG  Sample 
Tumor 
percentage as 
estimated by 
pathologist 
x       x V2490 100% tumor 
x x x   x 75247072 100% tumor 
x x x   x UR1526 90% tumor 
x x x   x UR1528 65% tumor 
x x   x x 88824362 100% tumor  
x x x   x UR1551 75% tumor 
x x x   x UR1552 100% tumor 
x x x x x UR1554 100% tumor 
x x x   x UR1556 100% tumor 
x 
 
    x UR1560 50% tumor 
x x x   x UR1562 100% tumor 
x       x UR1566 50% tumor 
x x x x x UR1568 90% tumor  
x x     x UR1569 95% tumor 
x       x UR1570 50% tumor 
x x x     UR1571 75% tumor 
x x x   x UR1577 75% tumor  
x x x   x UR1579 95% tumor  
x x x   x UR1581 100% tumor  
x x x   x UR1583 95% tumor  
        x UR1586 50% tumor  
x x x   x UR1587 90% tumor 
x       x UR1591 50% tumor 
x x x   x UR1593 100% tumor 
x x x   x UR1602 90% tumor 
x x x   x UR1603 90% tumor 
x x  x   x UR1605 95% tumor  
x x  x   x UR1606 95% tumor  
x x  x   x UR1607 100% tumor  
x x x   x UR1608 100% tumor  
x x  x   x UR1611 100% tumor  
x x  x   x UR1615 100% tumor  
x x  x   x UR1616 75% tumor 
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Supplementary table 5.3. Summary of alignment results over 54 samples   
  Average St. Dev.  Minimum Maximum 
Total number of reads (Mbp) 118,10 41,79 49,25 216,36 
Number of high quality aligned bases (Gbp) 10,38 3,79 4,30 18,95 
Mean read length 101 0 101 101 
Percentage targets with zero coverage 2,55 1,47 1,81 10,00 
Percentage of target bases covered at least 2x 95,84 1,95 86,15 97,07 
Percentage of target bases covered at least 10x 92,43 2,64 80,23 95,08 
Percentage of target bases covered at least 20x 86,10 5,09 73,34 93,37 
Percentage of target bases covered at least 30x 76,10 9,99 49,18 91,31 
 
 
 
 
 
 
 
 
Chapter 5 
 
104 
 
 
Supplementary figure 5.1. A representative example of a tumor genome for which copy numbers 
were determined by ASCAT. A. The LogR track quantifies the copy number of each genomic locus and 
can therefore be used to distinguish amplifications from deletions. The B-allele frequency or BAF 
shows the relative presence of each of the two alternative nucleotides at each SNP locus profiled and 
is used to distinguish which allele is amplified or deleted. B. The ASCAT profile contains the allele-
specific copy number of all assayed loci: the copy number is shown on the y axis, the genomic 
location on the x axis. The allele with the lowest copy number is shown in green, the allele with the 
highest copy number in red. Both lines are slightly shifted such that they do not overlap. 
Representative example of sample 88824362. 
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Supplementary figure 5.2. MeDIP-Seq and hMeDIP-Seq results of KLK2 and SLC45A3 genes. Figures 
are generated using the SeqMonk software, where the upper tags represent reads on the forward 
strand and lower tags reads on the reverse strand. Example for DNA isolated from the prostate of 
patient 88824362 with the A1908S mutation. 
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CHAPTER 6: 
GENERAL DISCUSSION AND PERSPECTIVES 
 
This study exemplifies how next-generation sequencing can contribute to a deeper understanding of 
the genetic landscape of PCa. We first analyzed two commonly used PCa cell lines (LNCaP and C4-2B) 
and consequently adopted the acquired knowledge and technological expertise to the analysis of 
high-risk PCa patient samples. This provided new insights into the genetics of PCa, revealed novel 
mutations and generated new hypotheses that can be tested in future research.  
 
6.1. MODEL SYSTEMS FOR PROSTATE CANCER 
6.1.1. Cell lines as models for prostate cancer 
In general, cell lines can be beautiful tools to study many aspects of tissue and cancer biology, in as 
far as they haven’t differentiated too much from the tissue they were derived from. This also holds 
true for PCa. In most cases, PCa is inherently slow growing, and morphologically and molecularly 
heterogeneous. Therefore, cells from prostate carcinomas are one of the most difficult cell types 
from which to establish continuous cell lines (van Bokhoven et al. 2003). Despite numerous attempts 
to derive cells from primary tumors, the frequently used model systems for PCa (LNCaP, DU145 and 
PC-3) were derived from metastatic lesions and either have lost the AR, or have a mutated AR. These 
immortalized cell lines are therefore not representative of primary disease. Be that as it may, LNCaP 
cells still express many prostate (cancer) markers, are androgen-dependent in their growth and 
hence can be used to study androgen transcription and cell cycle control.  
Unfortunately, each cell line represents only one tumor type and one cancer patient. Combining this 
with the heterogeneity of PCa, the reproduction of studies in several cell lines can lead to 
inconsistent or contradicting results. Nevertheless, cell lines are easily cultured, readily available and 
simple to use and therefore still used frequently in preclinical research. Novel models are being 
developed that should close the (preclinical) gap between studies on cell lines and clinical studies.  
 
6.1.2. Recent developments in prostate cancer model systems 
More and more evidence is emerging about the crucial interplay between tumor cells and their 
microenvironment during the development and progression of PCa. The tumor microenvironment 
denotes the intimate relationship between malignant cells and their surrounding stroma, which 
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includes fibroblasts, lymphocytes, blood vessels and extracellular matrix components (Centenera et 
al. 2013). The signaling between stromal and epithelial compartments is crucial for PCa development. 
Cell lines however do not accurately recapitulate the heterogeneity or complexity of this tissue 
microenvironment. 
Recent developments of novel model systems for PCa are the ex vivo cultures of biopsies (explants) 
and the patient-derived xenografts. As both models are derived from primary human tissues and still 
contain a stromal department, they represent more relevant systems to study PCa. The explant 
cultures allow taking into account the intrapatient heterogeneity as well as the extent of proliferative 
responses to steroid hormones (Centenera et al. 2012). Furthermore, this model allows the relatively 
rapid assessment of the antiproliferative activity of novel therapeutic agents in the tissue, without 
having to treat the individual patients (Centenera et al. 2013). Alternatively, xenografts may be 
derived directly from patient tissue without prior in vitro culture. This means that tumor tissue that is 
excised at the time of surgery is immediately transplanted into immune-deficient mice. As for the ex 
vivo culturing, this model allows testing different treatment options, together with the induction of 
castration-resistance (Lin et al. 2014).  
 
6.1.3. LNCaP and C4-2B cells as model system 
Despite recent advances in the development of novel model systems that more closely resemble the 
situation as it is in the patient, the LNCaP and C4-2B cells are still frequently used as a model for the 
progression of androgen-dependent to androgen-independent PCa. We therefore set out to 
catalogue all point mutations in the exomes of both cell lines. One should note that the field of 
massively parallel sequencing is rapidly evolving. Hence, the bioinformatics analyses and algorithms 
used in Chapter 3 (Variations in the exome of the LNCaP PCa cell line) and Chapter 4 (Comparative 
genomic and transcriptomic analyses of LNCaP and C4-2B PCa cell lines) were different. In the LNCaP 
exome in Chapter 3, the BWA, Bowtie, Samtools and Varscan algorithms, which were available at 
that time, were used. We reanalyzed this exome using BWA and GATK (Genome Analysis Toolkit) 
UnifiedGenotyper to be able to compare it with the exome of C4-2B cells (Chapter 4). For LNCaP 
cells, the differences between both analyses are relatively small, although each method identifies 
some mutations that are not identified with the other method. Currently, the field has evolved again 
and the GATK UnifiedGenotyper is now substituted by the HaplotypeCaller (GATK Best Practices).  
In both cell lines, we identified a surprisingly high number of mutations (between 1800 and 4000). 
The filtering used to obtain this number was very stringent in comparison to the filtering applied to 
primary PCa tissues. Nevertheless, we identified a 100 times more mutations in the cell lines than in 
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primary PCa. This could be attributed to the DNA mismatch repair deficiency, the metastatic origin of 
both cell lines as compared to primary tumor samples and the adaptation to the prolonged culturing 
(Chen et al. 2001, Leach et al. 2000). Although we have no knowledge as to the effect of each of 
these cell line mutations, one should be very careful when studying certain genes, as about 8% of all 
genes are mutated in these cells.  
The comparison of exome sequencing and transcriptome analyses of the LNCaP and C4-2B cells can 
be used to generate or test hypotheses for further research. We looked for an affected pathway that 
could explain the high metastatic potential of C4-2B and its preference to metastasize to bone, 
characteristics that are absent in the LNCaP cells. We found that the pathway converging on MLCK 
(myosin light chain kinase) might be a start for novel functional tests. However, since our primary 
goal was the sequencing of high-risk PCa and samples became available, we did not investigate this 
further.  
 
 
6.2. HIGH-RISK PROSTATE CANCER  
6.2.1. The high-risk Leuven cohort 
A Pan-cancer analysis revealed that genes mutated in over 20% of cancers have largely been 
discovered. However, only a handful of cancer genes are mutated at that high frequency, and most 
cancer genes that are mutated in patients occur at intermediate frequencies between 2 and 20% 
(Lawrence et al. 2014). To provide therapeutic options for most patients, it will therefore be critical 
to identify and understand the pathway-level implications of all genes mutated at intermediate 
frequencies. This means that, despite the fact that a relatively large number of PCa exomes have 
already been sequenced, it is still valuable to sequence novel exomes from new patient cohorts as 
we did in the present study. Specifically, the present study focused on high-risk PCa, resulting in a 
relatively homogeneous group. Our goal was not only to list novel mutated genes, but also to try to 
identify new cancer driver mutations by testing the functional consequences of specific mutations. 
Because the size of our cohort is relatively small (it is still growing), and because it is a prospective 
study, the generated data are currently mainly hypothesis-generating. It is crucial to first test these 
hypotheses in vitro (in cell lines) and in a retrospective study of the high-risk and lethal PCa samples 
collected at UZ Leuven, and then return to the clinic for further validation.  
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6.2.2. Planned experimental studies 
We identified a novel point mutation in the TET1 gene in one of the high-risk PCa samples. This 
mutation results in a partial loss of the DNA hydroxymethylating activity. However, we still need to 
investigate what the consequences of this mutation could be for tumor growth, tumor 
aggressiveness, tumor invasion and possible tumor lethality. Early experiments could involve using a 
PCa cell line that has a low endogenous expression of TET1 and then overexpress either wild type or 
mutant TET1. Growth and metastatic properties could then be analyzed in vitro or in xenotransplant 
studies. Alternatively, we could knockout the TET1 gene or introduce the mutation in a mouse model 
and subsequently check for PCa development (after crossing in other PCa mutations like PTEN 
deletion, the TMPRSS2-ERG fusion etcetera). This could be further correlated with changed TET1 
activity in primary and metastatic PCa.  
Similar to the TET1 mutation, we are currently investigating a novel point mutation in the eEF2K gene 
or the eukaryotic elongation factor-2 kinase. This kinase phosphorylates and inactivates eEF2, thus 
preventing eEF2 from binding to the ribosome and hence blocking protein synthesis (Figure 6.1.A). 
Many signaling pathways (such as MAPK and mTOR) control eEF2 activity, but this regulation is 
exerted exclusively via modification of eEF2K activity rather than eEF2 activity (Hizli et al. 2013). 
Increased eEF2K activity has been shown in some cancers, such as breast cancer (Parmer et al. 1999). 
In contrast, overexpression of eEF2 protein was detected in over 90% of gastric and colorectal 
cancers (Nakamura et al. 2009). Moreover, overexpression of eEF2 in a gastric cancer cell line 
significantly enhanced cell growth and in vivo tumorigenicity in a mouse xenograft model (Nakamura 
et al. 2009). Hypothesizing that the identified point mutation could change the enzymatic activity of 
eEF2K, we recently started to test the kinase activity both in prokaryotic and in eukaryotic cells. 
Furthermore, we would also like to test the effect of a mutation in the RFC1 gene (replication factor 
C 1). As the mutation in RFC1 is located in the PCNA binding domain, a first test would be to look at 
the capacity of wild type and mutated RFC1 to load PCNA and polymerase efficiently (Figure 6.1.B).  
Of course, the above mutations only represent three examples out of a list of more than 400 
mutations. The present challenge is to test the functional consequences of more of these mutations, 
in order to identify the driver mutation(s) in each PCa patient. 
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Figure 6.1. Hypothetical mechanisms of action of point mutations detected in high-risk PCa samples. 
A. In non-tumoral cells, eEF2 is phosphorylated and hence inactivated by eEF2K. As 
unphosphorylated eEF2 is required for the translation elongation, protein synthesis in these cells is 
limited. The detected mutation in eEF2K could inactivate the kinase, resulting in more active eEF2 
and enhanced protein synthesis. B. In normal circumstances, RFC1 is required for the recruitment of 
DNA polymerase to PCNA (proliferating cell nuclear antigen) to start DNA repair. The mutation in 
RFC1 could result in an impaired recruitment of the polymerase to the site of DNA repair.   
 
6.2.3. Goals of the PEARL consortium 
The high-risk PCa samples that were used in this study were collected within the frame of the PEARL 
(Prostate Cancer Research Leuven) consortium. The aim of the PEARL consortium is to prospectively 
integrate available data on exome sequencing, copy number alterations, lipidomics and DNA 
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methylation for a homogeneous cohort of high-risk PCa patients. The integration of these data with 
the data from the clinical research groups should allow the identification of biomarkers for PCa 
aggressiveness or lethality.  
Combining our patient exomes with the already published exomes, results in over 200 PCa samples. 
Despite the heterogeneity of PCa, this already gives us a view on the repertoire of protein-coding 
mutations. Nevertheless, the listing of all mutations is only the beginning of new research, as a lot of 
questions still need to be answered. Which mutations are drivers, and which are passengers? How 
does each driver mutation exerts its effect? Is it through changes in gene expression or changes in 
enzymatic activity? Which cellular processes will be affected and will this result in a proliferative 
advantage for the cancer cells?  If this is true, how will they do this? Will certain mutation profiles or 
affected pathways result in the identification of different PCa subtypes that have different clinical 
properties?  
 
 
6.3. MASSIVELY PARALLEL SEQUENCING 
6.3.1. What is next with massively parallel sequencing?  
Nowadays, most oncogenic variants that are identified are located in the coding genome, while the 
variation in the non-coding genome is largely ignored. The reason for this biased focus is purely 
practical: the effect of a coding mutation can be estimated or tested, while it is much more difficult, 
if not impossible, to determine the effect of a non-coding variant. Recently however, progress has 
been made to improve our understanding of the non-coding genome: The ENCODE project has 
assigned a biochemical function to 80% of the genome (Consortium et al. 2012). Incorporation of this 
knowledge will shift the discovery scale to the whole genome.  
Oncogenesis is a complicated integration of alterations of multiple signal transduction pathways. 
They are the result of changes at different levels including the genome, epigenome, transcriptome, 
proteome, metabolome, lipidome and changes in chromatin and histones. It remains to be 
determined to what extent mutations in microRNAs and cis-regulatory elements (for example a 
promoter region with a mutation in a transcription factor binding site) contribute to the oncogenic 
process (Aerts et al. 2013). An example here is a recurrent mutation in the core promoter of the TERT 
gene as detected in melanoma, that generates a binding site for ETS transcription factors which then 
leads to increased transcriptional activity of the TERT promoter (Huang et al. 2013).  
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We hope that the integration of different data sets for genome, epigenome and transcriptome will 
help us to unravel the intricate regulatory connections between genetics and cancer. This will add an 
additional layer of knowledge, as is exemplified in the study of Sharma et al. where cancer-specific 
changes in DNA binding by the AR as well as other transcription factors were identified (Sharma et al. 
2013).   
 
6.3.2. Implementation of personalized genomics in prostate cancer 
Personalized medicine is defined as the individual treatment of patients, by targeting the pathways 
that are present or activated in their tumors. In PCa as in many other cancers, there is a considerable 
amount of interindividual tumor heterogeneity both at the genetic and epigenetic level. This 
heterogeneity challenges the ‘one-fits-all’ approaches for cancer management and highlights the 
need for individualized treatment approaches. It is therefore a future challenge to divide patients in 
subgroups and then look per subgroup to define what is treatable and what is curable. Such a 
personalized approach to cancer care is often superior to the current non-personalized standard 
therapies. Hence, we need to stratify patients prognostically, not predictively. This stratification will 
most likely be based on genomic features. 
So far, molecular, clinical and pathologic research has focused on one tumor type at a time. However, 
due to the Cancer Genome Atlas Research Network (TCGA), it is now clear that cancers of disparate 
organs have many shared features, whereas, conversely, cancers from the same organ are often 
quite distinct (Cancer Genome Atlas Research et al. 2013). This implicates that somatic mutations 
that are rare in one tumor type, can be identified as drivers by aggregating events across different 
tumor types. This will improve detection of hotspot mutations which will ultimately lead to the 
identification of potential new drug targets. In other words, instead of treatments specific for PCa, it 
could become possible to treat one PCa in the same way as a colorectal cancer, if the same pathway 
in both patients is affected. This will only be possible by the study of larger cohorts of patients, as 
well as by a better understanding of the functional consequences of the identified alterations.  
Ultimately, the mutations in each individual PCa case and of course also of the metastatic disease 
should be identified by genomic pathology and these data should be taken into consideration during 
the personalized treatment of the patient. However, a lot of progression is still needed: the price of 
sequencing has to drop further, the techniques to take liquid biopsies in the form of circulating 
tumor cells or DNA should be enhanced, and last but not least, new therapies have to be developed 
that can make use of the mutations that occur in the cancer. Efforts are made at the moment to 
inhibit PI3K (activated by PTEN mutation), inhibit mutant ARs resistant to enzalutamide and 
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abiraterone, development of synthetic lethal strategies for p53, … It will be exciting to see the 
continuing evolution in these different domains.  
In conclusion, the introduction of next-generation sequencing in the clinic is an important step 
forward, even when much more work is still required to fully understand the oncogenome and to 
integrate it with the other available system biology approaches. 
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SUMMARY 
 
PCa is the second most frequently diagnosed cancer in males worldwide. A wide range of genomic 
alterations, including point mutations, copy number changes and rearrangements, can lead to the 
development of cancer. Due to the heterogeneity of PCa, it still remains a clinical challenge to 
differentiate indolent from very aggressive tumors. A better molecular profiling of the primary 
tumors should enable a better classification of the disease, ultimately providing information that 
could direct a more personalized treatment. One approach is to study the contribution of somatic 
base pair substitutions to the oncogenic process. 
Cancer cell lines are commonly used as laboratory resources to study basic molecular and cellular 
biology. For prostate cancer (PCa), LNCaPs are the most commonly used cells. However, information 
on protein-changing mutations, genetic heterogeneity and genetic (in)stability is largely lacking for 
these cells. In a first part, we used exome-sequencing to focus on missense and nonsense single 
nucleotide variants and short insertions and deletions. We detected 1802 non-synonymous point 
mutations and 218 small insertions and deletions. While most detected mutations were undescribed 
so far, we confirmed the known mutations in the androgen receptor and the PTEN gene. Surprisingly, 
we confirmed 38 out of 42 mutations in DNA and RNA from different monoclonal and polyclonal 
LNCaP derivatives. From this, we deduced that LNCaP cells are heterozygous for a large number of 
variants and that both the variant and the wild type allele can be simultaneously expressed as mRNA. 
The fact that mutations in the E-cadherin, CDK4, Notch1 and PlexinB1 genes are absent in some 
subclones, strongly indicates a degree of genetic instability. Finally, to help identify the mutations 
that are most likely drivers of the oncogenic process, we developed an in silico protocol, which can 
be adopted for other exome analyses. We provided an extensive database of genetic variations in the 
exome of LNCaP cells, and these should be taken into consideration when using LNCaPs as a model 
for PCa.  
The progression of PCa from androgen-dependent to androgen-independent poses an important 
clinical question, as the mechanisms leading to metastatic PCa are not well understood. C4-2B cells 
are derivatives of LNCaP cells, as they were derived from a bone metastasis that grew in nude mice 
after inoculation with the LNCaP-derived, castration-resistant C4-2 cells. The combination of LNCaP 
and C4-2B cells thus forms an excellent preclinical model to study the development of metastatic 
castration-resistant PCa. Because of the importance of this progression model, a second part of this 
study characterized both cell lines more thoroughly using exome and transcriptome sequencing to 
obtain point mutations and differential expression patterns. Exome sequencing detected 2188 and 
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3840 mutations in LNCaP and C4-2B cells respectively, of which 1784 were found in both cell lines. 
The use of more recent algorithms resulted in a higher sensitivity to detect point mutations, 
increasing the number of mutations detected in LNCaP from 1802 to 2188. Surprisingly, the parental 
LNCaP cells contained more than 400 mutations that were not found in the C4-2B exome. Moreover, 
more than half of the mutations found in the exomes of both cell lines were confirmed by analyzing 
the transcriptome sequencing data. The transcriptome data also revealed that 457 genes show 
increased expression and 246 genes show decreased expression in C4-2B cells as compared to LNCaP 
cells. Based on the list of C4-2B-specific point mutations and the list of differentially expressed genes, 
we detected changes in the focal adhesion and ECM-receptor interaction pathways which converged 
on the myosin light chain kinase gene. Whether this contributes to the metastatic potential of C4-2B 
cells remains to be investigated. To conclude, we provide lists of mutated genes and differentially 
expressed genes in the LNCaP and C4-2B PCa cell lines to all researchers interested in using these 
cells as preclinical models. 
A final component of this project used tissue from 27 patients with high-risk primary PCa. We 
performed exome sequencing and copy number profiling of 27 primary prostate tumors and their 
normal tissue pairs. Tumors having a PSA > 20 ng/ml, or Gleason score ≥ 8 or clinical stage ≥ T2c are 
known to have a high risk on disease recurrence after treatment. In addition to amplifications and 
deletions that were described before, we identified a novel recurrent amplification on 7p22.3. Exome 
sequencing revealed one hypermutated sample containing 451 mutations, compared to an average 
of 19 mutations in the other samples, indicating that DNA repair is compromised in this sample. This 
hypermutated tumor indeed harbored a mutation in the DNA-repair gene Replication Factor C. This 
mutation is predicted to affect the interaction with PCNA and hence the recruitment of DNA 
polymerase to PCNA. In a second tumor, we detected a novel point mutation in the TET1 gene. This 
methylcytosine dioxygenase converts 5-methylcytosine to 5-hydroxymethylcytosine, which leads to 
demethylation of cytosines and might lead to changes in gene expression or chromatin organization. 
Immunoprecipitation of methylated and hydroxymethylated DNA followed by deep-sequencing 
performed on the tumor sample containing the A1908S TET1 mutation demonstrated an overall 
hypo-hydroxymethylation and hypermethylation at specific genomic loci, when compared to two 
other tumor samples without mutation in TET1. This effect was corroborated by the in vitro effect of 
the mutation on the dioxygenase activity as assessed by dot blot assays. We further showed that 
there is an overlap between groups of androgen-regulated genes and the TET1-regulated genes. 
Moreover, in cotransfection experiments, TET1 seems to act as a coactivator of the androgen 
receptor. From the above data, we conclude that the A1908S TET1 mutation as detected in a primary 
PCa leads to partial loss of TET1 tumor suppressor activity.  
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PCa is, wereldwijd, de op één na meest frequent gediagnosticeerde kanker in mannen. Een groot 
aantal genomische veranderingen, zoals puntmutaties, veranderingen in aantal kopijen van een (stuk 
van een) chromosoom of herschikkingen van stukken van chromosomen, kunnen leiden tot het 
ontstaan van kanker. Door de heterogeniteit van PCa, is het nog steeds een uitdaging in de kliniek om 
een onderscheid te kunnen maken tussen indolente en agressieve tumoren. Een betere kennis van 
de moleculaire processen in deze tumoren kan uiteindelijk leiden tot een betere classificatie van de 
ziekte, en dit kan uiteindelijk resulteren in een meer gepersonaliseerde behandeling. Een eerste 
aanzet hiertoe is om de bijdrage van puntmutaties te onderzoeken. 
Kankercellijnen worden vaak gebruikt in het laboratorium om basisonderzoek te voeren naar 
moleculaire en cellulaire biologie. Voor prostaatkanker (PCa) zijn LNCaP cellen de meest gebruikte 
cellen. Toch is er nog niet veel geweten over mutaties, genetische heterogeniteit en instabiliteit in 
deze cellijn. Met behulp van exoom sequenties concentreerden we ons in een eerste onderdeel op 
puntmutaties die een aminozuur veranderen of die een stopcodon introduceren in een open 
leesraam of op korte inserties en deleties. Op deze manier detecteerden we 1802 puntmutaties en 
218 korte inserties en deleties. De meerderheid van de gedetecteerde mutaties waren tot nog toe 
onbekend, hoewel we ook de reeds gekende mutaties in de androgeenreceptor en in het PTEN gen 
terugvonden. Daarenboven konden we 38 van de 42 geteste mutaties bevestigen in zowel 
monoklonale als polyklonale afgeleiden van LNCaP. Dit leidde tot de conclusie dat LNCaP cellen 
heterozygoot zijn voor een groot aantal van de gevonden mutaties en dat zowel het mutante als het 
wild type allel tegelijkertijd tot expressie kunnen komen. Het feit dat we de mutaties in E-cadherine, 
CDK4, Notch1 en PlexinB1 niet terugvinden in bepaalde LNCaP subklonen, wijst er sterk op dat de 
LNCaPs genetisch instabiel zijn. Tot slot hebben we een in silico protocol ontwikkeld dat kan helpen 
bij het identificeren van mutaties die waarschijnlijk bijdragen tot het oncogeen proces. Dit protocol 
kan ook gebruikt worden bij andere exoom analyses. We stellen een uitgebreide databank van 
genetische variaties ter beschikking die we terugvonden in het exoom van de LNCaP cellen. Met de 
mutaties in deze lijst wordt best rekening gehouden als men LNCaP cellen gebruikt als model voor 
PCa.  
De mechanismen achter de evolutie van androgeen-afhankelijke naar androgeen-onafhankelijke PCa 
vormt een belangrijke klinische vraag, omdat de mechanismen die leiden tot metastatische PCa tot 
op heden niet goed begrepen zijn. C4-2B cellen zijn afgeleiden van de LNCaP cellen, aangezien ze 
werden geïsoleerd uit een botmetastase die groeide in naakte muizen nadat deze geïnoculeerd 
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werden met de castratie-resistente, van LNCaP cellen afgeleide, C4-2 cellen. De combinatie van 
LNCaP en C4-2B cellen vormt dus een uitstekend preklinisch model om de ontwikkeling van 
metastatische, castratie-resistente PCa te bestuderen. In een tweede project hebben we beide 
cellijnen uitgebreid gekarakteriseerd op het niveau van hun exoom en transcriptoom. Dit leidde tot 
de detectie van 2188 en 3840 puntmutaties in LNCaP en C4-2B cellen respectievelijk. Hiervan werden 
1784 mutaties gevonden in beide cellijnen. Doordat er bij deze karakterisatie recentere algoritmen 
gebruikt werden dan bij de eerdere analyse van LNCaP cellen, detecteerden we een hoger aantal 
mutaties: 2188 in plaats van 1802. Tot onze verbazing detecteerden we in de LNCaP cellen meer dan 
400 mutaties die niet werden teruggevonden in het exoom van C4-2B cellen. Door de sequenties van 
het exoom en het transcriptoom te vergelijken, konden we meer dan de helft van de mutaties die we 
detecteerden in het exoom ook terugvinden in het transcriptoom, en dit voor beide cellijnen. 
Daarenboven konden we uit het transcriptoom besluiten dat 457 genen verhoogd en 246 genen 
minder tot expressie kwamen in C4-2B cellen wanneer deze vergeleken werden met de expressie in 
LNCaP cellen. Door gebruik te maken van C4-2B-specifieke puntmutaties en dit te combineren met 
de lijst van genen die differentieel tot expressie komen, probeerden we een aantal verschillen terug 
te vinden die de grotere metastatische eigenschappen van C4-2B cellen zouden kunnen verklaren. 
We detecteerden veranderingen in adhesie en in de ECM-receptor interacties. Deze signaalcascades 
oefenen beiden invloed uit op het MLCK gen (myosin light chain kinase) wat de metastatische 
eigenschappen van C4-2B cellen zou kunnen verklaren. Deze studie resulteerde uiteindelijk in lijsten 
van gemuteerde genen en genen die differentieel tot expressie komen in de LNCaP en in de C4-2B 
cellijn.  
In een derde onderdeel van deze studie beschikten we over weefsels van 27 patiënten die in de 
kliniek momenteel worden ingeschat als hebbende een ‘hoog-risico’ op het terugkeren van de ziekte. 
Van deze 27 primaire tumore werd het exoom in sequentie gezet en amplificaties en deleties 
bepaald. We detecteerden verschillende recurrente genoomamplificaties en deleties die reeds 
gekend waren, maar we detecteerden ook een ongekende recurrente amplificatie op 7p22.3. De 
exoomsequenties toonden aan dat er één staal gehypermuteerd was: het bevatte 451 puntmutaties, 
terwijl er in de andere stalen gemiddeld slechts 19 mutaties teruggevonden werden. Dit zou er 
kunnen op wijzen dat het DNA herstel beïnvloed is in deze tumor. Inderdaad, we vonden een mutatie 
in het RFC1 gen (Replication Factor C 1) dat betrokken is bij het herstel van DNA. Van de mutatie in 
dit gen wordt voorspeld dat ze de interactie met PCNA zal beïnvloeden en dit zal op zijn beurt de 
interactie met het DNA polymerase beïnvloeden. In een tweede tumor vonden we een mutatie in het 
TET1 gen. Dit gen codeert voor een methylcytosine dioxygenase dat 5-methylcytosine omvormt tot 
5-hydroxymethylcytosine, wat uiteindelijk resulteert in demethylatie en veranderingen in 
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genexpressie. Een eerste experiment bestond uit de immunoprecipitatie van gemethyleerd en 
hydroxygemethyleerd DNA gevolgd door het in sequentie zetten van dit DNA. Het tumorstaal met de 
A1908S mutatie in TET1 toonde in het algemeen een hypo-hydroxymethylatie en een 
hypermethylatie op bepaalde genomische posities, wanneer dit vergeleken werd met twee 
tumorstalen zonder mutatie in TET1. Deze resultaten werden nog versterkt bij de dot blot 
experimenten, die het effect van de mutatie op de dioxygenase activiteit in vitro nakijken. TET1 lijkt 
ook een coactivator van de androgeenreceptor te zijn. Uit bovenstaande data concluderen we dat de 
A1908S mutatie in TET1 resulteert in een gedeeltelijk verlies van de TET1 tumor suppressor activiteit.  
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